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Sumário 
Um ambicioso objectivo em neurociências consiste em compreender como os 
genes afectam a biologia neuronal, a função sináptica e o comportamento. Os genes 
que se pensam estar envolvidos em doenças psiquiátricas atraem maior atenção 
devido à alta probabilidade da sua perturbação originar alterações salientes em 
processos neurobiológicos. Desta forma, estes genes permitem também uma melhor 
compreensão de questões biomédicas relevantes. Usando o ratinho (murganho) como 
animal modelo pode acelerar este processo de descoberta pois trata-se de uma 
espécie capaz de padecer de manipulações ao nível genético, permitindo assim a 
recriação ortóloga de mutações humanas. Ao mesmo tempo, o conhecimento actual da 
neurobiologia comportamental em ratinhos pode conectar certos endofenótipos como 
sendo reminiscentes de perturbações humanas. 
No meio pós-sináptico de neurónios glutamatérgicos encontra-se um 
aglomerado de proteínas essenciais para o funcionamento sináptico. Esta estrutura 
conhecida como densidade pós-sináptica, contém um vasto número de receptores de 
neurotransmissores, proteínas adaptadoras, proteínas de sinalização e proteínas de 
adesão, que desempenham um papel crucial na regulação da comunicação neuronal. 
Mais ainda, nos recentes anos, muitos dos genes que codificam estas proteínas da 
densidade pós-sináptica têm sido associados a um vasto leque de doenças 
psiquiátricas. No entanto, os mecanismos celulares envolvidos, os circuitos afectados 
in vivo e como estas mutações se traduzem em comportamentos anormais, permanece 
um fenómeno desconhecido para a vasta maioria destes mesmos genes.  
O trabalho apresentado nesta tese tem como objectivo compreender melhor a 
função de duas proteínas pós-sinápticas, a nArgBP2 (neural Arg-binding protein 2) e a 
Shank3 (SH3 and multiple ankyrin repeat domains protein 3). Estas proteínas foram 
seleccionadas pois ambas podem formar interacções directas com a proteína SAPAP3 
(SAP90/PSD-95-associated protein 3), a qual desempenha uma função crucial na 
densidade pós-sináptica. Por sua vez, em humanos, o gene Shank3 está fortemente 
associado ao desenvolvimento de autismo, enquanto o gene que codifica a nArgBP2 
está localizado numa região cromossomal que foi sugerida como uma região de 
susceptibilidade para a doença maníaco-depressiva. Utilizando uma estratégia 
multidimensional, este trabalho caracteriza a expressão e localização destes dois 
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genes no cérebro do ratinho e, através de engenharia genética, descreve as linhagens 
de ratinhos mutantes que foram produzidas para avaliar in vivo as consequências da 
disrupção de Shank3 e nArgBP2. 
A caracterização detalhada do RNAm do gene nArgBP2 no cérebro do ratinho 
mostra que este é expresso na parte frontal do cérebro. Um anticorpo anti-nArgBP2 foi 
gerado para caracterizar a expressão proteica ao longo do desenvolvimento e isto 
levou à observação de que existe um forte enriquecimento da proteína nArgBP2 na 
camada externa do giro dentado do hipocampo. Animais mutantes com uma disrupção 
da nArgBP2 apresentam comportamentos hiperactivos em ambientes novos e 
familiares, aumento de estereotipias, redução de comportamentos-tipo depressão e 
uma disfunção acentuada nos ritmos circadianos, todos estes endofenótipos 
característicos de comportamento-tipo maníaco. Para testar se estes comportamentos-
tipo maníacos poderiam ser revertidos foi administrado lítio, que se mostrou efectivo 
em melhorar vários dos comportamentos anormais, incluindo as disfunções nos ritmos 
circadianos e a redução de comportamentos-tipo depressão. Usando técnicas de 
electrofisiologia e bioquímica, descobriu-se um fortalecimento na sinalização 
glutamatérgica e também um aumento no nível de subunidades de receptores do 
glutamato. No conjunto, estes dados sugerem que a nArgBP2 pode desempenhar um 
papel importante na regulação do comportamento e das sinapses glutamatérgicas. 
Mutações e lesões no gene Shank3 estão na origem das complicações 
neurológicas presentes em pacientes afectados pela síndrome de Phelan-McDermid 
(SPM). Adicionalmente, mutações neste gene estão também presentes em doentes 
autistas que não apresentam SPM. Os fundamentos neurobiológicos e as disfunções 
sinápticas originadas pela perturbação do gene Shank3 são exploradas neste trabalho 
ao nível sináptico, dos circuitos neuronais e do comportamento. Por fim, das duas 
linhagens de ratinhos mutantes geradas para o gene Shank3, a mutação mais severa 
leva a que os animais exibam comportamentos repetitivos e injuriosos, e défices em 
interacções sociais, duas das três complicações comportamentais comummente 
observadas em pacientes autistas. Adicionalmente, uma análise celular, 
electrofisiológica e bioquímica, revela defeitos nas sinapses estriatais e nos circuitos 
cortico-estriatais em ratinhos mutantes para o gene Shank3. Este trabalho propõe que 
a Shank3 é um gene essencial para o desenvolvimento normal da conectividade 
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neuronal e apoia o modelo de que mutações no gene Shank3 levam ao 
desenvolvimento de doenças do espectro do autismo. 
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Summary 
Understanding how discrete genes affect neuronal biology, synaptic function 
and, ultimately, behavior is a major goal in neuroscience. Not surprisingly, genes 
believed to be involved in human psychiatric and developmental brain disorders garner 
the most attention due to the likelihood that their disruption will promote salient changes 
in neurobiological functions. They also promise to nurture further understanding of 
relevant biomedical questions. Using the mouse as a model organism accelerates this 
discovery process because the species is amenable to manipulation at the genetic 
level, allowing for the orthologous recreation of human mutations. Simultaneously, our 
understanding of murine behavioral outputs can now be linked to particular 
endophenotypes reminiscent of human disorders.  
One large cluster of proteins important for synaptic function is situated at the 
postsynaptic site of glutamatergic neurons. This structure, known as the postsynaptic 
density, contains large numbers of neurotransmitter receptors, scaffolding, signaling 
and adhesion proteins that play a critical role in the regulation of neuronal 
communication. Moreover, several of the genes which code for proteins of the 
postsynaptic density have in recent years been implicated in a wide spectrum of 
neuropsychiatric disorders. Nevertheless, the cellular mechanism involved, the 
neuronal circuits affected in vivo and the manner in which discrete mutations translate 
into behavioral abnormalities remain unknown for a large number of these genes. 
This project aimed at increasing our understanding of the function of two 
postsynaptic proteins, nArgBP2 (neural Arg-binding protein 2) and Shank3 (SH3 and 
multiple ankyrin repeat domains protein 3). These proteins were selected because both 
can form dyadic interaction with SAPAP3 (SAP90/PSD-95-associated protein 3), a key 
protein at the postsynaptic density. In humans, Shank3, in particular, has been strongly 
linked with the development of autism, while nArgBP2 sits in a chromosomal region 
possibly linked to bipolar disorder. Using a multi-level approach, this provides a detailed 
characterization of the localization and expression of these genes in the mouse brain. 
By means of genetic engineering, mutant mouse lines were also generated to probe the 
in vivo consequences of their disruption. 
A detailed characterization of nArgBP2 mRNA expression in the mouse brain 
demonstrates that it is widely expressed in the forebrain. Additionally, an anti-nArgBP2 
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antibody generated to characterize protein expression across development led to the 
observation of a striking enrichment of nArgBP2 in the outer molecular layer of the 
dentate gyrus. Furthermore, nArgBP2 disruption is shown to generate animals that 
display hyperactivity in novel environments and in the home cage, increased 
stereotypies, reduced depressive-like behaviors and a pronounced disruption in 
circadian rhythms, all endophenotypes of manic-like behavior. To test if the manic-like 
behaviors might be reversed, lithium was administered and shown to ameliorate several 
behavioral abnormalities including the circadian rhythm dysfunction and the reduced 
depressive-like behaviors. Probing the mutant animals at the electrophysiological and 
biochemical level uncovered an increase in glutamatergic signaling and in levels of 
glutamate receptor subunits at the synapse. Together, these results suggest that 
nArgBP2 may play an important role in the regulation of glutamatergic synapses and 
behavior. 
Mutations and lesions in the Shank3 gene are thought to be the main source of 
the neurological deficits seen in Phelan-McDermid syndrome (PMS) patients. 
Additionally, mutations in this gene are also present in autistic patients outside of 
diagnosed PMS. The neurobiological substrates and synaptic dysfunctions arising from 
the perturbation of the Shank3 gene are explored in this work at the synaptic, circuit 
and behavioral level. From the two Shank3 mutant mice lines generated, the most 
severe mutation led to animals that exhibited self-injurious repetitive grooming and 
deficits in social interaction, two of the three behavioral abnormalities seen in autistic 
individuals. Additionally, cellular, electrophysiological and biochemical analyses 
uncovered defects at striatal synapses and cortico-striatal circuits in the Shank3 mutant 
mice. This work suggests that Shank3 is a critical gene for the normal development of 
neuronal connectivity and further supports the involvement of mutations in the Shank3 
gene in autistic spectrum disorders. 
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Chapter 1 
General Introduction 
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Neuropsychiatric Disorders 
Overview of Neuropsychiatric Disorders 
The World Health Organization has estimated that 20 to 25% of all individuals 
will experience some form of mental or behavioral disorder during their lifetime. 
Assessments from 2001 show that neuropsychiatric disorders have a point prevalence 
of 10% in the general adult population, which in that year corresponded to 
approximately 450 million afflicted individuals (WHO, 2001). 
In terms of “years lost to a disability”, neuropsychiatric disorders are at the top of 
disability-causing diseases or disorders together and represent over a third of time lost 
while disabled. In 2004, the leading cause for disability was Unipolar Depressive 
Disorder which corresponded to 8.3% of the total disabilities for males and 13,4% for 
females. Schizophrenia and bipolar disorder, each representing 2 to 3% of years lost to 
a disability also rank consistently among the top leading global causes of medical 
burden for non-fatal disabling conditions (WHO, 2004b).  
These disorders also play an important role in economic cost to society. The 
aggregate yearly cost in the United States was pointed to be as high as 2.5% of the 
gross domestic product (Rice, 1990), while in the European Union it is situated between 
3% and 4%. Furthermore, the expenditure on health related mental disorders accounts 
for approximately 10-20% of the total health care costs in most European countries 
(Meerding et al., 1998; OECD, 2008; Patel and Knapp, 1998).  
Two large epidemiological studies summarized on Table 1, representing data 
collected in the 1980’s (NIMH, 1992) and 1990’s (Kessler et al., 1994), highlight the 
prevalence of discrete disorders in the US general adult population. Finally, in the more 
than 32,000 suicides in the United States in 2005, 90% of these were believed to be 
associated with a neuropsychiatric disorder (Insel, 2009).  
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Table 1. – 1-year prevalence of neuropsychiatric disorders in 18-54 year olds. *ECA 
study, Epidemiologic Catchment Area from 1980-1985 (NIMH, 1992). **NCS study, 
National Comorbidity Survey 1990-1992 (Kessler et al., 1994). ***Adapted from the 
“Report of the Surgeon General on mental health” (Satcher, 2000). GAD, 
generalized anxiety disorder; OCD, obsessive-compulsive disorder; PTSD, post-
traumatic stress disorder; MD, major depression; ASP, antisocial personality 
disorder. 
!
 
ECA* 
Prevalence (%) 
NCS** 
Prevalence (%) 
Best*** 
Estimate* (%) 
Any Anxiety Disorder 13.1 18.7 16.4 
Simple Phobia 8.3 8.6 8.3 
Social Phobia 2 7.4 2 
Agoraphobia 4.9 3.7 4.9 
GAD — 3.4 3.4 
Panic Disorder 1.6 2.2 1.6 
OCD 2.4 — 2.4 
PTSD — 3.6 3.6 
Any Mood Disorder 7.1 11.1 7.1 
MD Episode 6.5 10.1 6.5 
Unipolar MD 5.3 8.9 5.3 
Dysthymia 1.6 2.5 1.6 
Bipolar I 1.1 1.3 1.1 
Bipolar II 0.6 0.2 0.6 
Schizophrenia 1.3 — 1.3 
Nonaffective Psychosis — 0.2 0.2 
Somatization 0.2 — 0.2 
ASP 2.1 — 2.1 
Anorexia Nervosa 0.1 — 0.1 
Severe Cognitive Impairment 1.2 — 1.2 
    
Any Disorder 19.5 23.4 21 
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Mood Disorders 
Mood disorders encompass a number of psychiatric diagnoses which describe 
“disorders in which the fundamental disturbance is a change in affect or mood to 
depression (with or without associated anxiety) or to elation” (WHO, 2004a). Changes 
in the underlying mood are hypothesized to be the main feature in these disorders. 
These diagnosis broadly encompass both the manifestation of single episodes of 
depressive or manic diagnoses to a combination or oscillations between altered mood 
states (American Psychiatric Association, 2000).  
One end of the mood spectrum is occupied by Unipolar Depression (UPD or 
Major Depressive Disorder, MDD), a mental disorder characterized by a generalized 
low mood accompanied by low self-esteem and anhedonia. Patients in a depressive 
state experience strong emotions of sadness and grief which in contrast to a healthy 
individual do not remit when the external cause of these emotions is ameliorated. 
Additionally, these emotions can also be disproportionate to their underlying cause or 
occur without any triggering external effects (Belmaker and Agam, 2008; Wakefield et 
al., 2007). Clinically, the diagnosis for UPD requires the observation of distinct altered 
emotional state and the presence of several psychophysiological changes. These 
primarily include a depressed mood (subjective or reported by others) and a markedly 
diminished interest in pleasurable activities (anhedonia). Physiological signs can 
include significant weight loss or weight gain, disturbed sleep patterns with episodes of 
insomnia or hypersomnia, extreme fatigue, psychomotor agitation and slowing of 
speech and action. Other common symptoms described by patients include: feelings of 
worthlessness, guilt, indecisiveness, diminished ability to think and concentrate and 
recurrent suicidal thoughts. Diagnostic for UPD is usually attained when several of 
these symptoms persist for a minimum of 2 weeks and interfere considerably with work 
and family relations (American Psychiatric Association, 2000). Depressive episodes in 
UPD are also highly recurrent. Of the individuals who suffer a single episode, 60% of 
them go on to develop a second, and of those, 70% recur in a third episode (American 
Psychiatric Association., 2000). Depression also tends to emerge early in adolescence 
and progress into adulthood suggesting a developmental course in neuropathogenesis 
(Kim-Cohen et al., 2003; Pine et al., 1998). 
Milder or circumstantial forms of depression include Dysthymic Disorder, 
Psychotic Major Depression, Postpartum Depression and Seasonal Affective Disorder.   
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Dysthymia originates from the ancient Greek word for “bad mood”. This disorder 
is defined by milder, non-disabling symptoms that persist for two years or longer 
(Akiskal, 1983; American Psychiatric Association, 2000). Dysthymia is an independent 
diagnosis but can also be present in the course of a major depressive state. 
Specifically, a long term study has shown that patients with major depressive disorder 
spent on average 44% of their course in a low-grade depressive state (dysthymic) and 
only 15% of time in major depressive episodes (Judd et al., 1998).  
Psychotic depression is characterized by the presence of delusions or 
hallucinations and specific biological alterations, including a chronic over-activation in 
the production of glucocorticoids  (Schatzberg et al., 1985). This latter observation has 
led to the successful treatment of Psychotic Major Depression with glucocorticoid 
receptor antagonists (Belanoff et al., 2001; Schatzberg et al., 1983). Furthermore, 
Psychotic Major Depression is more resistant to classic pharmacological treatments 
than non-psychotic MDD while on the other hand, electroconvulsive therapy was 
reported as more effective for Psychotic Major Depression (Buchan et al., 1992; 
Petrides et al., 2001).  
Postpartum dysphoric mood states comprise a range of severity, from the 
commonly denominated “baby blues” (a highly prevalent disorder of a mild and 
transient nature) to the more severe and persistent Postpartum Affective Psychosis and 
Postpartum Depression. In Western countries the incidence of Postpartum Depression, 
in particular, has been reported to be as high as 10-20% (Grace et al., 2003; Hopkins et 
al., 1984). 
Lastly, and originally described by Rosenthal and colleagues at the NIH, 
Seasonal Affective Disorder is also described as change in mood. Most commonly 
associated with depression affect occurring during the winter (or less frequently in the 
summer) (Rosenthal et al., 1984), Seasonal Affective Disorder is also positively 
correlated to latitude and diminished duration of daytime light (Rosen et al., 1990; Vera, 
1998).  
Mood disorders also include the Bipolar Spectrum Disorders; these are 
characterized by a combination of clinical manifestation of elevated moods (mania or 
hypomania if symptoms are milder), depressive episodes, or mixed episodes 
(simultaneous characteristics of mania and depression). In manic episodes a psychotic 
state can also be present with symptoms of delusions and hallucinations (American 
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Psychiatric Association, 2000). Bipolar and unipolar disorders share overlapping 
symptomatology; namely in the presence of episodes of depression in certain forms of 
bipolar illness. However, the distinction in nosological diagnosis between these two 
types of mood disorders is supported by distinct differences in disease outcome, 
response to pharmacological treatment and genetic studies (Farmer and McGuffin, 
1989; Kendell, 1987). 
Bipolar Spectrum Disorders are also subdivided into several categories: for 
Bipolar I Disorder (BPDI), a positive diagnostic includes at least one manic or mixed 
episode (i.e. dysphoric mania or agitated depression) with or without concurrent 
episodes of hypomania or major depression. Bipolar II Disorder (BPDII) is diagnosed 
with the occurrence of at least one hypomanic episode and one major depressive 
episode. Additionally, in BPDII, depressive episodes are more frequent and more 
intense than manic episodes. Furthermore, some individuals can undergo what is 
known as “rapid cycling”, a condition in which depressive (dysthymic) and manic 
(euphoric) states rapidly alternate (Dunner et al., 1977). Interestingly, tricyclic 
antidepressants can induce rapid cycling in bipolar patients (Wehr and Goodwin, 1979). 
Finally, another bipolar-like state includes Cyclothymia, a condition considered to be the 
most milder form of the bipolar spectrum, where affected patients exhibit both 
hypomanic and mild depressive states (Akiskal et al., 1977). 
Historically, depression and mania are some of the oldest known forms of 
mental disorder. Predating psychiatry by several centuries, Hippocrates was the first to 
describe these illnesses as disconnected from mysticism and supernatural causes, but 
instead linked them to a biological cause originating in the brain (Zarate and Manji, 
2009). Recently, with the contemporary advent of human genetics, epidemiological 
studies and heightened clinical awareness, the potential genetic influences that 
precipitate these disorders have garnered substantial interest.!
! !
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Heritability of Mood Disorders 
The heritability of UPD and BPD was originally addressed from quantitative data 
obtained from interviews of affected patients and family members (James and 
Chapman, 1975; McGuffin et al., 1988; Reich et al., 1987; Smeraldi et al., 1977; 
Trzebiatowska-Trzeciak, 1977). The prevalence of similar disorders in first degree 
relatives was found to be consistently higher than the expected value for the general 
population. For UPD, in particular, incidences as high as 15% and 20% have been 
reported for first degree relatives (Shih et al., 2004; Sullivan et al., 2000). A meta-
analysis study on familial transmission, twin studies and environmental influences led 
Sullivan and colleagues to propose that: “Major depression is a familial disorder, and its 
familiality mostly or entirely results from genetic influences.” (Sullivan et al., 2000).  
In terms of gender, although there is strong evidence that UPD affects more 
women than men (Kessler et al., 1993; Weissman et al., 1993), most studies do not find 
significant differences in the genetic heritability between males and females (Kendler 
and Prescott, 1999; Lyons et al., 1998; McGuffin et al., 1996), suggesting that both 
genders share the majority, but not totality of genetic influences for UPD (Kendler and 
Prescott, 1999; Sullivan et al., 2000).  
Genetic heritability also plays a major role in the development of Bipolar 
Disorder (Andreasen et al., 1987; Goldin et al., 1983; Reich et al., 1969; Weissman et 
al., 1984). Interestingly, the lifetime risk of mood disorders for relatives of bipolar 
patients was reported to be higher than that for unipolar probands (24% versus 20%) 
(Ciaranello and Ciaranello, 1991; Meltzer, 1987). Furthermore, the lifetime risk of 
bipolar disorder in relatives of bipolar probands is 40-70% for monozygotic twins and 5-
10% for first degree relatives, whereas an overall risk in the general population of 0.5-
1% suggests a 10-20 fold increase in risk for first degree relatives of afflicted individuals 
(Craddock and Jones, 1999). 
The precise model for the genetic transmission of bipolar and unipolar disease, 
however, remains somewhat elusive. Some studies have supported the hypothesis of 
some disease causing loci, arguing in favor of Mendelian inheritance. Nevertheless, 
most studies have not excluded the possibility for polygenic or multifactorial models. 
This suggests the possibility of a mixed model of inheritance or a combination between 
single gene mutations and disease predisposition due to the interaction between 
multiple genes (Ciaranello and Ciaranello, 1991; Craddock and Jones, 1999; Lau and 
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Eley, 2010; Zarate and Manji, 2009). Additional factors play a role confounding the 
interpretation of genetic inheritance, these include: assortative pairing (defined by the 
tendency for individuals with related phenotypes to mate more commonly than what 
would be expected by random chance) (Baron et al., 1981; Mathews and Reus, 2001; 
Merikangas et al., 1988), genetic anticipation (surfacing of symptoms at an earlier age 
in familial transmission as it is passed on to the next generation) (Lange and McInnis, 
2002; McInnis et al., 1993; Nylander et al., 1994), genomic imprinting (McMahon et al., 
1995; Ohara et al., 1998) or potential effects from mitochondrial genes (Clay et al., 
2010; Kato and Kato, 2000; McMahon et al., 1995).  
It is therefore clear that bipolar disorder is a complex genetic disorder. However, the 
high heritability of this condition has attracted intensive research activity aiming at 
identifying disease causing mutations or mutations associated with increased 
susceptibility to BPD. Surprisingly, large quantities of data from human genetics, in the 
form of linkage and association studies have identified a multitude of putative regions of 
interest for BPD susceptibility in virtually every human chromosome except the Y 
chromosome (Figure 1). These results have muddled a strong conclusion as far as 
precise genetic influences on the etiology of this disorder but have, nonetheless, put 
forward a few “hot spot” regions, which have been reproducibly identified by 
independent groups of researchers (Serretti and Mandelli, 2008).  
Linkage and association studies suffer from a major confound in the form of 
reports which are not reproduced across different populations, as well as deficiencies in 
attaining wide statistical significance in several studies. These can be in part due to 
limited sample sizes and/or high degree of genotypical heterogeneity. Recently, more 
encompassing genome-wide studies are able to identify single nucleotide 
polymorphisms across the entire genome of each individual. Up to 2011, six genome-
wide association studies have been published for bipolar disorder (Baum et al., 2008; 
Ferreira et al., 2008; Scott et al., 2009; Sklar et al., 2008; Smith et al., 2009; WTCCC, 
2007). These studies present the upside of providing an unbiased identification of 
putative novel target genes, but at the same time may miss important rare causative 
mutations. On the other hand, genome-wide approaches often identify targets whose 
disease mechanisms remain obscure and only a few targets ascribed to neurobiological 
relevant pathways (Soronen et al., 2010). Conversely, the approach more commonly 
explored in neurobiology research, known as “candidate gene approach”, devotes 
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specific attention to genes that are known to be involved in biological pathways relating 
to the disease. Importantly, the synergy between unbiased genomic approaches and 
target based approach has put forward several promising targets that may be involved 
in the neuropathology of BPD. 
 
Bipolar Disorder 
Candidate Genes for Bipolar Disorder 
Mutations in the promoter region of the serotonin transporter -SLC6A4- in the 
17q11 region have been implicated in several studies into BPD. Multiple groups have 
identifying a 44 base pair insertion/deletion and another polymorphism in the second 
intron of the gene as potentially being involved in BPD (Anguelova et al., 2003; Heils et 
al., 1996; Lasky-Su et al., 2005; Lesch et al., 1996; Rotondo et al., 2002). The 
tryptophan hydroxylase (TPH) protein is the rate-limiting enzyme in the synthesis of 
serotonin. In humans, TPH1 and TPH2 proteins are coded by two separate genes with 
only TPH2 (in chromosome 12q21) being strongly expressed in the brain (Walther et 
al., 2003). TPH2 polymorphisms have also been implicated in susceptibility to BPD 
(Cichon et al., 2008; Grigoroiu-Serbanescu et al., 2008; Harvey et al., 2007; Lopez et 
al., 2007; Van Den Bogaert et al., 2006).  
Dopamine, like serotonin, is a monoaminergic neurotransmitter, and genes 
involved in the dopamine signaling pathway have also been implicated in mood 
disorders. The Dopamine Receptor D4 (11p15), the Dopamine Receptor D1 (5p35) and 
the Dopamine Transporter -SLC6A3-(5p15) have all been suggested to be linked to 
BPD (Del Zompo et al., 2007; Greenwood et al., 2001; Greenwood et al., 2006; Lopez 
Leon et al., 2005).  
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Figure 1. – Chromosomal regions associated with bipolar disorder. Thicker 
arrows indicate stronger evidence (multiple reports). Figure adapted from 
(Serretti and Mandelli, 2008) and chromosome ideograms from (David 
Adler, Univ. of Washington).  
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The Disrupted-in-Schizophrenia-1 (DISC1) gene (1q42) is another candidate gene 
for which there is strong evidence implicating its dysfunction in BPD (Blackwood et al., 
2001; Hodgkinson et al., 2004; Palo et al., 2007). This clear overlap in a gene 
potentially involved in schizophrenia as well as BPD is perhaps not surprising given the 
endophenotypical similarities between the two disorders (Zarate and Manji, 2009). 
Other strongly implicated genes include the D-amino acid oxidase activator (DAOA) 
(13q33) (Detera-Wadleigh and McMahon, 2006), FAT1 (4q35) (Abou Jamra et al., 
2008; Blair et al., 2006), the Brain-derived neurotrophic factor (BDNF) (11p14) 
(Kanazawa et al., 2007; Sklar et al., 2002) and interestingly, the aryl hydrocarbon 
receptor nuclear translocator-like protein (ARNTL, also known as Bmal1) (11p15) which 
heterodimerizes with the CLOCK gene as part of the molecular regulation of circadian 
rhythms (discussed below) (Mansour et al., 2006; Nievergelt et al., 2006). 
Gene Cellular role Chromosome 
location 
SLC6A4 Serotonin reuptake 17q11 
TPH2 Rate-limiting enzyme in 
the synthesis of serotonin 
12q21 
DRD4 Dopamine receptor 11p15 
DRD1 Dopamine receptor 5p35 
SLC6A3 Dopamine reuptake 5p15 
DISC1 Multiple cellular roles 1q42 
DAOA Indirectly involved in the 
activation of NMDA 
receptors 
13q33 
FAT1 Adhesion molecule 
and/or signaling receptor 
(Cadherin-related family) 
4q35 
BDNF Neurotrophin 11p14 
ARNTL (Bmal1) Circadian clock 11p15 
 
Table 2. – Genes strongly implicated in the Bipolar Disorder which have 
also been explored at the neurobiological level in potentially relevant cellular 
and signaling pathways.  
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Sleep and Bipolar Disorder 
Sleeping disorders have long been associated with mood disorders. 
Disturbances in sleep are included as part of the symptomatology for the diagnoses of 
both MDD (when present as hypersomnia or insomnia) and BPD, where reduced need 
for sleep can be part of a positive diagnostic for manic episodes (American Psychiatric 
Association, 2000). Classically, sleep deregulation has often been considered an 
epiphenomena of mood disorders and not necessarily a causal or primary driving force 
for either UPD or BPD, but more so, a consequence of the individuals’ altered mood. 
Recently, however, a shift in paradigm is emerging whereby a deeper understanding of 
the biology of circadian rhythms and their relationship to mood disorders is seen as an 
important mechanism contributing to the genesis and/or maintenance of mood 
disorders (Harvey, 2001; Harvey, 2011; McCrae and Lichstein, 2001; NIH, 2005).  
Both insomnia or hypersomnia are highly prevalent in UPD, with 60% to 84% of 
patients reporting sleep related symptoms (Ford and Kamerow, 1989). Insomnia is also 
hypothesized to precede and constitute a risk factor for depression (Riemann and 
Voderholzer, 2003). Interestingly, in a 20 year study from a representative sample of 
the Swiss population (Vollrath et al., 1989), researchers uncovered that long lasting 
insomnia predicted major depressive episodes. Specifically, 17% to 50% of subjects 
with insomnia lasting more than 2 weeks developed a major depressive episode at a 
later time (Riemann and Voderholzer, 2003).  
In BPD, 69 to 99% of patients experiencing manic episodes report a reduction in 
time spent sleeping. Furthermore, in the course of a depressive episode 23-78% 
experience hypersomnia (Harvey, 2008). Finally, in the inter-episode periods, BPD 
patients report sleep disturbances with a higher degree of fragmentation in the 
sleep/wake rhythm when comparing to healthy patients (Jones et al., 2005). 
Additionally, sleep disturbances have been described as an early warning signal 
for both manic and depressive bipolar episodes. In a meta-analysis of seventy-three 
publications of prodromal symptoms in BPD and UPD covering a total of 1191 subjects, 
it was uncovered that most patients were able to identify early symptoms of mood 
deregulation relapse. Specifically, the most robust early symptom of mania was sleep 
disturbance, as reported by 77% of BPD patients (Jackson et al., 2003). Moreover, 
bipolar patients are generally more capable of accurately detecting prodromal 
symptoms of relapse into manic episodes than they are of identifying relapses into 
!
14!
depressive episodes (Jackson et al., 2003; Sierra et al., 2007). Additionally, sleep 
disturbances not only predate recurrence into manic episodes, but they can also predict 
the first onset into BPD. A study performed in high-risk offspring (i.e. children coming 
from families in which one parent was diagnosed with BPD) concluded that sleep 
disturbances and anxiety disorders were antecedent conditions to develop BPD (Duffy 
et al., 2007). 
Interestingly, sleep deprivation (partial or total), or circadian phase advances in 
the sleep-wake cycle have long been known to produce an antidepressant effect in 
bipolar patients undergoing depressive episodes (Barbini et al., 1998; Wehr et al., 
1979; Wu et al., 2009). This effect has been hypothesized to be linked to different 
mechanism, including the serotonergic system (Benedetti et al., 2008), the 
dopaminergic system (Ebert and Berger, 1998) or as a consequence of a rebound or 
reset in the Process S (slow wave sleep) sleep stage (Endo et al., 1998; Endo et al., 
1997). 
Sleep is one of the biological processes controlled by circadian rhythms. The 
understanding of the molecular underpinnings of mammalian circadian rhythms has 
seen a surge in recent years. The circadian control of sleep and wakefulness, the 
genes and molecules involved and the understanding of the neural circuits that play a 
role in these processes are paving new discoveries into the neurobiology of mood 
disorders. Therefore, it is acknowledged that a deeper comprehension in the molecular 
biology of circadian rhythms can provide new clues into the etiology of Bipolar Disorder 
as well as new avenues for treatment (Jones, 2001).!
 
Circadian Rhythms 
Circadian rhythms regulate not only sleep and wakefulness but also body 
temperature, feeding, drug metabolism, hormone secretion, cell-cycle progression and 
glucose homeostasis. Circadian cycles themselves synchronize with the natural 
environment through the light-dark cycle. The circadian period length refers to the real-
time duration from a reference point during the course of a full cycle. In laboratory 
animals entrained to a 12h/12h light-dark cycle, the period duration is 24h. However, in 
the absence of the photonic entrainment cues, the internal clock usually displays 
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subjective period lengths that usually deviates from a 24h duration (Schwartz and 
Zimmerman, 1990) and although light is the predominant Zeitgeber (time giver), 
entrainment to a 24h cycle can also occur with other stimuli, such as food availability 
(Lax et al., 1999) or social cues (Goel and Lee, 1997).  
The “master clock” for the mammalian brain is present in the Suprachiasmatic 
Nucleus (SCN). Synchronization through daily dark-light cycle originates in 
photosensitive retinal ganglion cells which function independently of photoreceptor 
cones and rods and project to the SCN via the retinohypothalamic tract and thus initiate 
photonic entrainment (Berson, 2007; Berson et al., 2002). However, humans that are 
completely blind and display “free-running” circadian rhythms, melatonin can be 
administered to promote circadian entrainment (Sack et al., 2000). 
The discovery of the molecular networks involved in circadian pacemaking was 
originally tackled using random induced-mutagenesis in the fruit fly. This led to the 
identification of the per (period) gene which, depending on the mutation, generated both 
longer, shorter or arrhythmic periods (Konopka and Benzer, 1971). In wildtype flies it 
was later discovered that the levels of the per gene undergo an oscillation which 
approximates the circadian period (Hardin et al., 1990). More recently, advances in 
mouse molecular genetics have permitted the unraveling of mammalian circadian 
biology. One landmark study was the identification of the Clock gene (Circadian 
Locomotor Output Cycles Kaput) (Vitaterna et al., 1994). Using forward genetics, 
Vitaterna and colleagues induced random mutations in the gametes of male mice using 
ENU (N-ethyl-N-nitrosourea), and subsequently phenotyped 304 mice for disrupted 
circadian behavior. From these, they identified one mutant animal with a period 1 hour 
longer that its founder parent. Homozygocity of the mutated locus led to a disrupted, 
arrhythmic circadian period. Cloning of the gene and functional rescue of the Clock-
mutant mice using bacterial artificial chromosome (BAC) transgenic rescue was also 
accomplished by the same group (Antoch et al., 1997; King et al., 1997). Interestingly, 
however, the ENU induced mutation produces a single nucleotide change in a splice 
acceptor region in intron 19 (ClockΔ19) which induces an exon skipping and 51 amino 
acid deletion (King et al., 1997). More recently, a targeted deletion of exon 4 and 5 in 
the Clock gene generated a mouse line with a null allele for this gene (Debruyne et al., 
2006). Surprisingly, this line of mice displayed minimal aberrations in circadian patterns, 
suggesting that the ClockΔ19 may function as a dominant negative.  
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In contrast, homozygous mice for a deletion of Bmal1, a critical binding partner 
for Clock and an essential molecule in the molecular circadian regulation, display a 
complete loss of circadian rhythmicity in free-running conditions at both the behavioral 
and molecular level (Bunger et al., 2000). CLOCK and BMAL1 heterodimerize in the 
cytoplasm before entry into the nucleus, this is followed by phosphorylation events 
which promote their function as a transcriptional complex. With the above observations 
from mouse molecular genetics, this suggests that BMAL1 is essential for the 
transcriptional control and circadian oscillations, whereas, Clock can be functionally 
substituted by another protein (Debruyne et al., 2006). One possible candidate is 
Npas2, which has been suggested as having an overlapping role with Clock in the 
mouse brain (DeBruyne et al., 2007). At the molecular level, CLOCK interacts with 
BMAL1 to activate Per (period homologue) and Cry (cryptochrome) genes. PER and 
CRY can then heterodimerize, translocate to the nucleus, interact with the 
CLOCK:BMAL1 complex to inhibit self-expression (i.e. PER and CRY). During 
subjective evening, the PER:CRY repressor complex is degraded and the 
CLOCK:BMAL1 complex initiates a new cycle of transcription (Takahashi et al., 2008). 
Although these molecular pathways are central to circadian biology there are other 
known pathways that intersect this protein expression and degradation cycles which are 
summarized in Figure 2. 
Interestingly, the link between circadian rhythms and bipolar disorder has also 
been explored using the ClockΔ19 mice (Roybal et al., 2007). These mice display a 
strong preference for rewarding stimuli when compared to controls, a symptom present 
in bipolar patients during manic episodes, and also display less time immobile in the 
forced swim test (a measure of depression) as well as other behavioral abnormalities 
consistent with a model for mania. 
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Symptoms of mania Clock mutant mice 
Disrupted circadian rhythms Disrupted circadian rhythms 
Hyperactivity Hyperactivity 
Decreased sleep Decreased sleep 
Feelings of extreme euphoria Hyperhedonia/less helplessness 
Increased risk-taking Reduced anxiety 
Propensity toward drug abuse Increased preference for 
cocaine 
!
Table 3. – Clock display behavioral abnormalities consistent with symptoms 
from bipolar patients in the manic state. 
 
Moreover, lithium salts, which are administered as a mood stabilizer for BPD 
patients, ameliorates several of the behavioral abnormalities in the ClockΔ19 mice in 
measures of anxiety- and depression-related behavioral tasks (Roybal et al., 2007).  
Therefore, it is now acknowledged that circadian biology is well positioned to play 
a major role in BPD. Moreover, human genetic data and mouse modeling have 
implicated several of the genes crucial for normal circadian to susceptibility to BPD. 
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Figure 2. – The mammalian circadian clock is composed of a transcriptional–
translational feedback network. The circadian clock is composed of a primary 
negative feedback loop involving several genes, these include: Clock (and 
Npas2), Bmal1, Per1, Per2, Cry1 and Cry2. CLOCK (or NPAS2) and BMAL1 are 
transcription factors that activate transcription of Per and Cry. The resulting PER 
and CRY proteins heterodimerize, translocate to the nucleus and interact with the 
CLOCK:BMAL1 complex to inhibit their own transcription. After a period of time, 
the PER:CRY repressor complex is degraded and CLOCK:BMAL1 initiate a new 
cycle of transcription. A secondary autoregulatory feedback loop is composed of 
Rev:erba, which is another direct target of the CLOCK:BMAL1 transcription 
complex. REV:ERBA represses Bmal1 transcription and competes with a retinoic 
acid-related orphan receptor (ROR) to bind ROR response elements (RREs) in 
the Bmal1 promoter. Post-translational modification and degradation are another 
mechanism playing a role in circadian periodicity. Casein kinase 1 delta 
(CSNK1D) and CSNK1E are proteins involved in the phosphorylation of clock 
proteins, which in turn targets these proteins for polyubiquitylation and 
degradation by the proteosomal system. PER and CRY proteins are targeted for 
degradation by the β-TrCP1 and FBXL3 E3 ubiquitin ligase complexes. Legend: 
CCG (clock-controlled genes); CREB (cAMP response element-binding); E-box 
(BMAL1:CLOCK consensus binding regions); MAPK (mitogen-activated protein 
kinase); SCF (SCF E3 ubiquitin ligase); Ub (ubiquitin). Reprinted with permission 
from Macmillan Publishers Limited, ref 2579550687171, (Takahashi et al., 2008). 
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Modeling Bipolar Disorder 
Although mouse models of BPD have been proposed, the critical feature of 
bipolar cycling between mania and depression has not been successfully observed for 
genetic mouse models. It is unknown if this limitation is inherent to the murine model or 
if the manipulations performed have yet to tap on a truly cyclic pathological pendulum 
capable of pushing mice from depressive-like into manic-like behavior. Nevertheless, 
useful models of depression and of mania have been reported which replicate several 
of the features of both types of episodes. 
Several pharmacological models of BPD have been proposed in rodents. 
Amphetamines and other psychostimulants, such as D-amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA) and cocaine can induce psychomotor 
hyperactivity in mammals (Koob and Bloom, 1988). Administration of psychostimulants, 
amphetamines or methamphetamines, have been used to simulate manic episodes and 
a concomitant administration of therapies, such as lithium, valproic acid or transcranial 
magnetic stimulation can successfully rescue pathological behaviors (Frey et al., 
2006a; Frey et al., 2006b; Gould et al., 2001; Shaldivin et al., 2001). Repeated 
administration of methamphetamines, cocaine or morphine can produce behavioral 
sensitization and be used as a model of bipolar disorder which produces some cyclical 
manic-depressive activity. Again, the behavioral effect produced by these drugs are 
reversed or prevented by administration of lithium (Antelman et al., 1998; Kucinski et 
al., 1998; Namima et al., 1999). Of particular interest, in one study, a model of repeated 
high-dose cocaine administration produces behavioral hyperactivity response on some 
days and behavioral hypoactivity on alternating days (Antelman et al., 1998). Another 
pharmacological model for BPD includes the combination of amphetamine and 
chlordiazepoxide to induce hyperactivity, which can be rescued by lithium treatment 
(Vale and Ratcliffe, 1987). The drug ouabain, an inhibitor of the sodium-potassium 
pump, has also been used to model mania. This drug is known to induce hyperactivity 
in rodents, again an effect which can be countered by administration of lithium (El-
Mallakh et al., 2003; Li et al., 1997). 
The Nucleus Accumbens (NAc) and the prefrontal cortex (PFC) contain a 
central part of the neural circuitry that controls the expression of conditioned responses 
to amphetamine and cocaine-related motor hyperactivity (Franklin and Druhan, 2000). 
Several of these psychostimulants are known to increase dopamine content in the NAc. 
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The acute locomotor hyperactivity due to amphetamines and metamphetamine can be 
suppressed by Dopamine D1 and D2 receptor antagonists or Dopamine D2 Receptor 
(D2) agonist –quinpirole- (Kuribara and Uchihashi, 1993; Steketee and Kalivas, 1992). 
Amphetamines and cocaine tap into the dopamine neurotransmission by promoting an 
increase of presynaptic dopamine release (Jones et al., 1998; Kokoshka et al., 1998) 
and cocaine by blocking the reuptake of dopamine (Kitayama et al., 1992; Ritz et al., 
1987). Therefore, strong evidences suggest this neurotransmitter may be involved in 
the development of mania (Diehl and Gershon, 1992). 
One interesting behaviorally-induced model for mania involves inducing sleep-
deprivation. Originally developed to study sleep deprivation in cats (Jouvet et al., 1964), 
a common version of this test in rodents prevents sleep by stationing the animal in a 
platform covered in water. At the onset of REM sleep, muscle relaxation puts the animal 
in contact with water and induces awakening. This test, compounds sleep deprivation 
with other stressors such as social isolation, immobilization and contact with water, 
which impart several behavioral responses similar to idiopathic mania. Interestingly, 
haloperidol and lithium treatment reduced the sleep deprivation induced manic 
behavioral manifestations (Gessa et al., 1995).  
Another behavioral model is the dominant–submissive test to study mania and 
depression. Animals screened in this test display mania-like or depression-like behavior 
depending on their social position. Interestingly, this effect was determined to be 
reversed by anti-manic or anti-depressive drugs (Malatynska and Knapp, 2005; 
Malatynska et al., 2007). 
With the above described ClockΔ19 mice, other genetically manipulated animals 
have also been proposed to model aspects of BPD. At the most basic level, these 
include the analysis of the inbred strains of laboratory mice (Einat, 2007). Others 
include the Disrupted-in-Schizophrenia 1 gene (DISC1) originally identified in a Scottish 
family strongly afflicted by schizophrenia and mood disorders. Although not thoroughly 
explored, mutant mice for DISC1 remains an interesting putative model for bipolar 
disorder (Ishizuka et al., 2006; Lipina et al., 2010; O'Tuathaigh et al., 2007).  
Glucocorticoid receptors modulate stress response and cognitive functions 
linked to mood disorders (Yehuda et al., 1993). Animal models designed to perturb 
glucocorticoid receptor function have been generated and shown to display several 
endophenotypes relevant to BPD and UPD. An antisense RNA transgenic mouse for 
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the glucocorticoid receptor displays obesity and increased activity in the HPA 
(Hypothalamic–pituitary–adrenal) axis, consistent with severe depression (Pepin et al., 
1992). Treatment of these animals with moclobemide, a monoamine oxidase type A 
inhibitor, reverted both behavioral and hormonal alterations (Montkowski et al., 1995). 
Another mouse model includes a forebrain specific over-expression of the 
glucocorticoid receptor. These animals displayed increased depression-like behaviors, 
anxiety-like behaviors, hypersensitivity to cocaine administration and a high sensitivity 
to anti-depressants (Wei et al., 2004). In addition to the above, there are other 
manipulations on this same gene which promote relevant phenotypes to depression in 
the mouse. Interestingly, one group simultaneously examined two lines of mutant mice, 
one with a heterozygous reduction in glucocorticoid receptor expression, and the other 
with an overexpression of the receptor. Similarly to the other loss of function mutants, 
the reduction in expression generated an animal prone to depression, while the 
overexpression produced an animal resistant to depression (Ridder et al., 2005); 
however, this is different from what was seen in an earlier model of glucocorticoid 
receptor overexpression (Wei et al., 2004). 
The 22q11 deletion in humans is associated with a conserved deletion of 
approximately 40 genes which impart a high risk for mental disorders, most notably 
schizophrenia and early onset BPD (Papolos et al., 1996). The prevalence of 22q11 
deletion syndrome is estimated to be approximately 1:6000 in the live births, making 
this syndrome the second most common chromosomal disorder (after Down’s 
syndrome) and the most common microdeletion syndrome  (Botto et al., 2003; 
Devriendt et al., 1998; Paylor and Lindsay, 2006). One of the most robust findings in a 
mouse model of 22q11 microdeletion are deficiencies in sensory motor gating (Kimber 
et al., 1999). This endophenotype is mostly linked to schizophrenia in humans (Braff 
and Geyer, 1990; Braff et al., 2001), but nevertheless may also be strongly linked to 
bipolar disorder since BPD patients also display sensory motor gating deficits (Perry et 
al., 2001). 
The Glycogen synthase kinase 3 gene which produces the two isoforms, GSK-
3α and GSK-3β, is intimately linked with the glycogen metabolism but is also important 
in several downstream signaling pathways of neuronal receptors (e.g. growth factors, 
neurotransmitters and neurotrophins). GSK-3β in particular has been implicated in 
bipolar disorder and also as a potential target for lithium’s therapeutic effect in mood 
!
22!
stabilization (Gould et al., 2004). GSK-3β has also been linked to regulation of the 
circadian rhythm (Kaladchibachi et al., 2007). Pharmacologically, GSK-3β is efficiently 
inhibited by lithium and valproate, both of which are used to treat BPD (Chen et al., 
1999; Klein and Melton, 1996). Interestingly, transgenic mice overexpressing GSK-3β 
express several features reminiscent of mania when tested behaviorally, these 
included, hypophagia, increased locomotor activity and decreased habituations in the 
open field test and increased acoustic startle response with decreased habituation 
(Prickaerts et al., 2006).  
The Protein kinase C interacting protein (PKCI) is a small protein belonging to 
the histidine triad family proteins. In a meta-analysis of 12 microarray studies of bipolar 
disorder, this gene was found to be decreased in the dorsolateral PFC (Elashoff et al., 
2007). Relevant for mood disorders, the PKCI/HINT1 mutant mice display less 
immobility in the forced swim and the tail suspension tests, both of which are indicative 
of lower levels of depression. These animals are also less anxious than their wildtype 
littermates, at the same time as the HPA axis activity was reported to be potentiated in 
the knockouts (Barbier and Wang, 2009). 
Electrophysiological kindling has also been used to model aspects of BPD (Post 
et al., 2001). This procedure has been used to indirectly address illness progression 
and development of new BPD episodes (Machado-Vieira et al., 2004). A typical kindling 
paradigm involves a daily subthreshold stimulation of the amygdala. With the 
progression of stimulations, same intensity depolarization leads to motor seizures and, 
subsequently, the occurrence of spontaneous seizures in the absence of stimulation 
(Goddard et al., 1969; Racine, 1972). Phenotypically, kindled rats display an increase in 
“emotionality” and increased resistance to capture in an open field test (Kalynchuk et 
al., 1998). On a similar paradigm hippocampal kindling  induces increased locomotor 
activity, which can be suppressed by the injection of a D2 receptor antagonist in the 
NAc (Leung et al., 2000). Nevertheless, the validity of the kindled model directly relating 
to the pathophysiological mechanisms of BPD is controversial (Post and Weiss, 1998). 
As detailed above, there are a considerable number of avenues to model bipolar 
disorder in laboratory animals. Validation of these models according to set criteria is 
therefore a necessity to establish which procedures garner the best approximation to 
the human condition. The rationale for this validation is generally broken in three 
categories, face validity, construct validity and predictive validity. Face validity is 
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attained when phenomenological similarities are seen between the model and the 
studied phenomena (i.e. the animal displays behavioral responses reminiscent of the 
human condition). Construct validity references to a strong theoretical support for the 
model (i.e. targeting a gene which is implicated in a human disorder). Predictive validity 
pertains at correcting abnormalities in the model after treatments or manipulations 
which replicate what is seen in affected individuals after homologous treatments (e.g. 
correction of behavioral defects in a model of BPD following a treatment with lithium) 
(Boulton et al., 1991).  
In BPD research, most models only approximate neuropathogenesis to a certain 
degree. Most pharmacological models display a good level of face validity but are 
somewhat lacking in construct validity (i.e. most bipolar onsets are not brought about by 
amphetamine or cocaine administration). On the other hand, genetic models display in 
some cases robust construct validity but only moderately approximate face validity (e.g. 
none of the genetic models display cyclic manic-depressive episodes). Predictive 
validity however is somewhat robustly attained across most modalities when measuring 
responsiveness to conventional treatment in reverting phenotypical manifestations (e.g. 
lithium or other pharmacological treatments successfully correct several abnormal 
phenotypes in the majority of models).  
Together, the models exemplified above detail important aspects of behavioral 
alterations related to face validity. Nevertheless, although a substantial amount of 
information is still lacking on the neurobiological and synaptic subtracts involved in 
bipolar pathogenesis, recent advances in studying both human patients and the 
aforementioned models provide some indications on potential commonalities in 
synaptic dysfunctions, neural circuit dysfunction and how drug treatments like lithium 
may affect the underlying mechanisms of this disorder.! !
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Model Main effects Relevant Reference 
Amphetamine 
Hyperactivity/ Reversibility and prevention of 
symptoms by Li, valproic acid or transcranial 
magnetic stimulation 
(Frey et al., 2006a; 
Frey et al., 2006b; 
Gould et al., 2001; 
Shaldivin et al., 2001) 
Metamphetamines Hyperactivity/ reversibility of symptoms by Li (Namima et al., 1999) 
Cocaine Potential cycling model of BPD (Antelman et al., 1998) 
Morphine Oscillatory effects on shock induced hypoalgesia/ Li attenuates phenotype (Kucinski et al., 1998) 
Amphetamine & 
chlordiazepoxide Hyperactivity/ reversibility of symptoms by Li 
(Vale and Ratcliffe, 
1987) 
Ouabain Hyperactivity/ reversibility of symptoms by Li (El-Mallakh et al., 2003; Li et al., 1997) 
Sleep deprivation 
Insomnia, hyperactivity, irritability, 
aggressiveness, hypersexuality and 
increased stereotypies/ Behavioral effects 
reverted by haloperidol or lithium 
(Gessa et al., 1995) 
Dominance-
submission 
Drugs used to treat mania inhibit the 
dominant behavior| Antidepressants 
counteract the behavioral consequences of 
encounter defeats 
(Malatynska et al., 
2007) 
ClockΔ19 
Hyperactivity, decreased sleep, lowered 
depression-like behavior, lower anxiety, 
increase in the reward value for cocaine and 
sucrose/lithium rescues phenotypes 
(Roybal et al., 2007) 
DISC1 Hyperactivity, deficits in PPI, deficits in sociability 
(Ishizuka et al., 2006; 
Lipina et al., 2010; 
O'Tuathaigh et al., 
2007) 
22q11 deletion Deficits in sensory motor gating 
(Paylor and Lindsay, 
2006; Paylor et al., 
2001) 
GSK-3β 
overexpression 
Hypophagia, increased locomotor activity 
with decreased habituations, increased 
acoustic startle response with decreased 
habituation 
(Prickaerts et al., 
2006) 
PKCI mutant mice Less anxious, less prone to depression, increased HPA axis activity 
(Barbier and Wang, 
2009) 
 
Amygdala and 
hippocampal 
kindling 
Increase in emotionality response/increased 
activity in the open field reverted by D2 
antagonist 
(Kalynchuk et al., 
1998; Leung et al., 
2000) 
 
Table 4. – Bipolar models, main face and main predictive validity and relevant 
references. 
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Circuit Dysfunctions in Bipolar Disorder 
The neural networks most strongly implicated as dysfunctional in BPD patients 
are comprised of the prefrontal cortical-striatal-limbic circuits. These regions form a key 
system in the control of complex socio-emotional behaviors (Cerullo et al., 2009; 
Strakowski et al., 2005). Broadly, prefrontal cortical areas are involved in executive 
function, decision-making and attention. Most notably, damage to orbitofrontal cortex is 
known to affect patients and produce impairments in everyday decisions-making, whilst 
simultaneously not affecting most other cognitive abilities (Wallis, 2007). Perhaps the 
two most well studied examples of damage to frontal cortical regions are the case of 
Phineas Gage and patient EVR. Both men were reported to display intact functioning in 
higher cognition (memory, reading and writing, verbal communication, sensorial 
processing, facial recognition and fine motor function) but an extremely damaged 
decision-making process profoundly altered their personalities and behaviors (Damasio, 
2005; Eslinger and Damasio, 1985). In terms of circuitry, the PFC receives afferent 
connections from all sensorial modalities (Carmichael and Price, 1995b; Cavada et al., 
2000). Conversely, projections from the PFC extend to synapse onto premotor cortical 
neurons as well as somatosensory association cortical structures. Additionally, the PFC 
is known to heavily converge onto limbic regions (amygdala, cingulate gyrus, 
hippocampus and thalamus) (Carmichael and Price, 1995a) and the striatum (Haber et 
al., 1995; Kemp and Powell, 1970).  
The second brain area involved in BPD is the striatum. The striatum is a major 
component of the basal ganglia which is comprised of a group of forebrain nuclei that 
receive inputs from the cortex and that in turn project to the thalamus. This circuit 
delineates the cortical-striatal-thalamic-cortical loop and is the canonical circuit involved 
in motor control planning and execution (Albin et al., 1989). Notably, both Parkinson 
and Huntington’s disease involve a perturbation in the main type of striatal neurons, the 
medium spiny neurons, either due to their loss in the case of Huntington’s disease or 
dysfunctionality due to lack of dopamine in the case of Parkinson’s disease (Albin et al., 
1989; DeLong, 1990). The striatum, and more broadly the basal ganglia in general, is 
also critically involved in the neuronal processes of habit formation, procedural memory 
formation, regulation of stereotypical behaviors and regulation of social interactions 
(Graybiel, 2008; Krach et al., 2010). 
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Lastly, the limbic system is also hypothesized to be involved in the broad 
neuronal circuitry potentially dysfunctional in BPD. Even though this structure is 
comprised of several well defined brain sub-regions, there is no precise 
neuroanatomical consensus as to which of these compose the limbic system (LeDoux, 
2000). The amygdala, cingulate gyrus, hippocampus, thalamus and hypothalamus are 
some of the more “consensual limbic areas”. Functionally, the limbic system is 
classically described as an important hub for memory formation, arousal and autonomic 
nervous system (Stephen et al., 1997).  
The cortical-striatal-limbic circuits were the focus of several neuroimaging 
studies, such as magnetic resonance imaging (MRI) and positron emission 
tomography. These approaches provide clues into the neuroanatomical abnormalities 
that may underlay BPD. Largely, most studies using imaging approaches analyzing 
whole brain volumes, report either normal size or a small decrease in whole brain 
volume in BPD patients (Arnone et al., 2009; Strakowski et al., 2005). Nevertheless, 
more circumscribed regional differences have been observed in prefrontal cortical 
regions, limbic areas and in the basal ganglia nuclei. The subgenual prefrontal cortex 
was reported to be smaller in patients with mood disorders (Drevets et al., 1997; 
Hirayasu et al., 1999). In the basal ganglia, however, some reports have pointed to a 
larger striatal size in bipolar patients (Aylward et al., 1994; Noga et al., 2001; 
Strakowski et al., 1999) or no significant differences (Brambilla et al., 2001; Strakowski 
et al., 2005), while other reports have shown an anisotropy in discrete basal ganglia 
structures (Haznedar et al., 2005; Hwang et al., 2006). Interestingly, when comparing 
between BPD and UPD patients with healthy controls, structural enlargement of the 
basal ganglia and amygdala have been observed in BPD, whereas these structures 
appear to be smaller in UPD patients (Strakowski et al., 2002a). The hippocampus is 
also implicated in BPD; however, studies looking at this region display conflicting 
reports in the literature, with both smaller (Blumberg et al., 2003; Frazier et al., 2005; 
Strakowski et al., 2002b; Strasser et al., 2005; Swayze et al., 1992) and larger 
hippocampal volumes (Beyer et al., 2004; Strakowski et al., 1999) having been 
reported. Importantly, one confounding factor that may explain these discrepancies (not 
only for hippocampus but also other regions under investigation) is the medication 
history and how that may play a role in brain volume. This was best addressed in one 
influential work where the authors analyzed unmedicated BPD patients, BPD patients 
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on a lithium treatment, BPD patients under a different drug treatment (the 
anticonvulsantes valproic acid or lamotrigine) and healthy controls. In this work, there 
was a trend for a smaller hippocampal region in untreated BPD patients when 
compared to controls, but conversely, an  increased hippocampal volume in lithium 
treated patients when compared to healthy controls (Yucel et al., 2008). This finding 
highlights the potential neuronal effects of this drug in humans and addresses some of 
the conflicting evidences in the field pertaining to anatomical brain volume.  
Nevertheless, even though structural abnormalities provide some clues into 
affected neural circuits, functional MRI (fMRI) has also been used to probe how brain 
regions are affected in terms of neuronal activity. One work found an increase in 
amygdala activation and a reduction in dorsolateral prefrontal cortex activation in 
response to fearful facial stimuli (Yurgelun-Todd et al., 2000). The same group 
however, found an increase in dorsolateral prefrontal cortex and decrease anterior 
cingulate cortex (limbic system) activation during a cognitive test (Gruber et al., 2004). 
BPD patients also display increased activation in the amygdala, thalamus, 
hypothalamus (limbic system) and medial globus pallidus (basal ganglia) (Malhi et al., 
2004). Qualitatively similar results were found by a separate group where patients 
observing hostile faces had greater activation in the limbic regions (left amygdala) and 
the basal ganglia region (nucleus accumbens and  putamen) (Rich et al., 2006).  
Interestingly, some researchers have proposed that UPD and BPD can perhaps 
be distinguished based on fMRI activation patterns. Specifically, responses to positive 
and negative emotional expressions in BPD patients revealed increased subcortical 
and ventral PFC responses, when comparing to healthy controls or UPD patients 
(Lawrence et al., 2004). It is worth noting however, that even though these studies are 
informative, they carry some limitations in interpretation. Confounding factors include 
not only the effect of medication on neuronal activation patterns, but also the 
contaminating effect that comorbid conditions may have on neuronal activity. Also, 
while some studies look at whole brain during imaging, many only analyze discrete 
regions of interest. Finally, experimental differences in the tasks performed by patients 
during fMRI analysis make a combined analysis of data across multiple research 
groups difficult to attain (Yurgelun-Todd and Ross, 2006).  
Nevertheless, fMRI studies in BPD patients have provided an interesting 
framework to understand and identify the neural circuits disrupted in this disorder. 
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(Yurgelun-Todd and Ross, 2006). At the same time, this information provides important 
and complementary information when attempting to model BPD with genetic mouse 
model and broadly point to an over-activation of neuronal circuits in BPD.  
 
Synaptic Dysfunctions in Bipolar Disorder 
At the most fundamental level, the behavioral manifestations in neuropsychiatric 
disorders are a direct consequence of dysfunction in neuronal communication. 
Specifically, schizophrenia, autism and mood disorders are an example of disorders 
which have accrued significant converging evidence implicating synaptic dysfunction to 
their respective etiological basis  (Bourgeron, 2009; Sanacora et al., 2008; Sodhi et al., 
2008). For BPD, key findings pertaining to molecular dysfunctions are postulated to 
affect either the neurons as a whole or specifically the signaling networks at the 
postsynaptic site. Therefore, the molecular complexity of the postsynaptic site may be 
of key interest in understanding BPD and how synaptic dysfunction may contribute to 
the development of this disorder.  
Chemical synapses are by far the most abundant types of synapses in the 
mammalian brain (Kandel et al., 2000). These specialized cell-cell junctions mediate 
the assymetrical flow of information from the pre-synaptic neuron to the postsynaptic 
cell. Notably, neurotransmitters exert specialized effects in the downstream cell but can 
in some cases influence the releasing neuron itself (Starke, 1981). The varied types of 
neurotransmitters available in the central nervous system provide a substantial pool for 
combinatorial information processing in neurons. For mood disorders in particular, the 
monoaminergic systems (serotonin, noradrenalin and dopamine) have been the focus 
of intense research; nevertheless, growing evidence implicates the glutamatergic 
system as potentially underlying the molecular pathways for these disorders (Sanacora 
et al., 2008). One interesting hypothesis is that even though monoaminergic 
neurotransmitters play an important role in the amelioration of symptoms in UPD and 
BPD, glutamatergic regulation of synaptic and neural plasticity is central to the etiology 
and treatment of these neuropsychiatric disorders (Manji et al., 2000; Payne et al., 
2002; Sanacora et al., 2008).  
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In the mammalian brain, glutamate is the most abundant excitatory 
neurotransmitter (Purves, 2008). Glutamatergic synapses form the prototypical 
junctions and the ones that best represent the asymmetric nature of information flow 
between neurons in the central nervous system. In these types of synapses, glutamate 
is released from the axonal presynaptic bouton onto the synaptic cleft. The 
neurotransmitter then transverses the synaptic cleft to bind and activating glutamate 
receptors on the postsynaptic neuron and generate excitatory postsynaptic currents 
(EPSCs) or changes in intracellular biochemical processes (Kandel et al., 2000). The 
glutamate receptors which effect this communication are subdivided into two major 
subtypes, ionotropic and metabotropic glutamate receptors. Metabotropic glutamate 
receptors (mGluRs) are G-protein-coupled receptors further subdivided into three 
groups, group I (mGluR1a–d, mGluR5a,b), group II (mGluR2 and mGluR3) and group 
III (mGluR4, mGluR6–8). These transmembrane receptors transduce neurotransmitter 
binding to intracellular activation of phospholipase C, modulation of adenylyl cyclase 
and through other second messengers (Conn and Pin, 1997). Glutamate ionotropic 
receptors are also subdivided according to their physiological and pharmacological 
properties into three groups, the N-Methyl-D-aspartic acid (NMDA)  glutamate 
receptors; the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
glutamate receptors and kainate receptors (Dingledine et al., 1999). Ionotropic 
glutamate receptors are ligand gated channels which depending on physiological 
conditions and selective permeability, allow the passage of ions across the cell 
membrane. 
In recent decades a large body of research has been devoted to the 
understanding of the proteinaceous synaptic machinery at both the presynaptic and 
postsynaptic site (Kennedy, 2000; Trimble et al., 1991). In the postsynaptic site, 
glutamate receptors cluster at high densities in the postsynaptic membrane through the 
action of a complex network of proteins known as the postsynaptic density (PSD) 
(Kennedy, 2000; O'Brien et al., 1998). The PSD was originally observed under electron 
microscopy of brain tissue as an electron dense material present beneath the plasma 
membrane of most postsynaptic sites (Palay, 1956a; b; Palay and Palade, 1955). This 
structure was latter characterized as being composed of several different proteins 
serving a multitude of intracellular functions (Carlin et al., 1983; Collins et al., 2006; 
Kennedy et al., 1983; Okabe, 2007). Using a combination of biochemical purification of  
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PSDs and proteomic analysis,  over 1000 different types of proteins at varying 
stoichiometric ratios have been identified at the PSD (Sheng and Hoogenraad, 2007). 
Interestingly, many of these proteins are not only present at the PSD, but are also 
biochemically enriched at this structure, when comparing the relative abundance 
between the PSD and the synaptic cytoplasm (Collins et al., 2006). By function, some 
of the best characterized types of PSD protein include: glutamate neurotransmitter 
receptors; scaffolding and adaptor proteins involved in the anchoring, trafficking and 
regulation of postsynaptic receptors; cell-adhesion molecules, which form contact 
across the synaptic cleft; kinases involved in downstream signaling and proteins 
involved in interaction and remodeling  of the actin cytoskeleton (Sheng and 
Hoogenraad, 2007).  
The molecular function of many of these proteins revolves around the formation 
of defined macro-molecular complexes which orchestrate biochemical function in 
discrete sub-networks. The NMDA glutamate receptors, known to play an important role 
for synaptic plasticity and cellular information processing (Daw et al., 1993; Malenka 
and Nicoll, 1993), form one of the largest complexes within the PSD (Husi and Grant, 
2001; Husi et al., 2000). One example is the NMDA receptor/MAGUK-associated 
signaling complex (MASC), named after the receptors and their primary interaction 
proteins, the “membrane associated guanylate kinase” (MAGUK) family of proteins. The 
MASC complex is composed of at least 186 different proteins which form a 2000 KDa 
structure within the larger PSD (Collins et al., 2006; Husi and Grant, 2001). Other large 
complex is formed by mGluRs which can associate with at least 64 other types of 
proteins (Farr et al., 2004) and AMPA receptors complex which directly or indirectly 
associate with at least 9 other proteins in the PSD (Collins et al., 2006).  
Abnormalities in glutamatergic biology in patients affected by mood disorders 
have been found in the cerebral spinal fluid, serum, plasma and brain tissue (Altamura 
et al., 1993; Francis et al., 1989; Frye et al., 2007; Kim et al., 1982; Levine et al., 2000; 
Mauri et al., 1998; Mitani et al., 2006). However, the majority of these studies were 
performed with samples from UPD patients. In one study however, increased levels of 
glutamate were observed in the frontal cortex of UPD and BPD patients (Hashimoto et 
al., 2007). Nevertheless, one important cavet with most studies performed in human 
patients, is the confounding effect of the medications prescribed affecting glutamate or 
glutamate receptor levels. Nevertheless, the alterations brought about by mood 
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disorder therapeutics can themselves be informative on the underlying mechanisms 
surrounding BPD. 
Mood stabilizer drugs, such as lithium and valproic acid, are generally 
prescribed to BPD patients to alleviate manic episodes and also to prevent recurrent 
manic-depressive oscillations. In cultured neurons, lithium displays a protective effect 
on NMDA mediated excitotoxicity due to calcium influx (Hashimoto et al., 2002; Nonaka 
et al., 1998). Indirectly, this suggests that abnormality in glutamatergic 
neurotransmission may underlay certain cellular aspects of BPD. Also, AMPA receptor 
function is known to be modulated by both lithium and valproic acid. It is interesting that 
although these two drugs are structurally dissimilar, both are able to affect AMPA 
receptor synaptic expression (Du et al., 2004). Specifically, both drugs lead to a 
downregulation of AMPA receptor GluR1 and GluR2 subunits, while conversely,  the 
antidepressant drug imipramine, which can trigger manic episodes, increases synaptic 
expression of GluR1 in hippocampus in vivo (Du et al., 2008; Du et al., 2004). 
It is therefore not surprising that synaptic and postsynaptic proteins directly or 
indirectly involved in the anchoring, regulation and trafficking of glutamate receptors 
may play a role in psychiatric disorders in general or in BPD in particular. In fact, 
several canonical PSD scaffolding proteins are strongly implicated in a multitude of 
disorders, such as mental retardation (SAP102 – synapse associated protein 102 a 
MAGUK), autism (Shank3 – SH3 and multiple ankyrin repeat domains protein 3) or 
obsessive-compulsive disorder (SAPAP3 - SAP90/PSD95-associated protein 3) 
(Bienvenu et al., 2009; Durand et al., 2007; Tarpey et al., 2004; Welch et al., 2007).!
 
Shank/SAPAP/nArgBP2 protein network at the PSD 
The Shank family of proteins is a group of PSD proteins coded by three 
independent genes, Shank1-3 (Lim et al., 1999). Shank proteins (Shank1-3) bind to 
SAPAP and participate in the PSD95/SAPAP/Shank complex (Kim et al., 1997; 
Takeuchi et al., 1997). This complex functions as a scaffold and is involved in the 
assembly of macromolecular signaling complexes and trafficking of ionotropic 
glutamate receptors (Malinow and Malenka, 2002; Nicoll et al., 2006; Prybylowski and 
Wenthold, 2004). This complex is also involved in the formation and maintenance of 
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dendritic spines (Elias and Nicoll, 2007; Hung et al., 2008; Roussignol et al., 2005; 
Welch et al., 2007).  Importantly, genetic disruption of Shank3 is thought to be a 
primary cause for the deficits in the 22q13.3 deletion syndrome (Phelan-McDermid 
syndrome), a syndrome characterized by the presence of autistic symptoms in a high 
percentage of affected individuals (Discussed in next section) (Abrahams and 
Geschwind, 2008).  
The SAPAP family of proteins is another group of proteins involved in the 
regulation of the PSD and glutamate receptors (Takeuchi et al., 1997; Welch et al., 
2007; Welch et al., 2004). SAPAP3, in particular, binds to Shank3 and has also been 
demonstrated to affect NMDA receptors at the PSD (Welch et al., 2007). In vivo, mutant 
mice for the SAPAP3 gene display OCD-like behaviors which are ameliorated by the 
administration of fluoxetine (Welch et al., 2007). In humans, mutations in the SAPAP3 
gene have also been identified in OCD patients (Bienvenu et al., 2009; Boardman et al., 
2010; Zuchner et al., 2009). Interestingly, both SAPAP3 and Shank3 proteins are 
enriched in the striatum and both mutant animals display cortico-striatal defects (Peca 
et al., 2011; Welch et al., 2007). 
nArgBP2 (neural Arg-binding protein 2) is another binding partner to SAPAP3 
identified using a Yeast Two-hybrid screening (Kawabe et al., 1999). This protein is the 
neuronal specific form of ArgBP2, a protein which associates and is a phosphorylation 
target for Abl and Arg protein-tyrosine kinases (Wang et al., 1997). ArgBP2 and 
nArgBP2 are reported to closely regulate multiple mechanisms converging on the 
cytoskeleton (Cestra et al., 2005; Ronty et al., 2005). At the same time, ArgBP2 was 
also identified to be present at the nucleus (Kioka et al., 2002; Wang et al., 1997). 
nArgBP2 however, is specifically expressed in the brain, much like SAPAP3 and 
Shank3, and is also highly enriched in the PSD. Therefore, nArgBP2 is well positioned 
to bridge the interaction between the PSD and the actin cytoskeleton (Cestra et al., 
2005; Kawabe et al., 1999). In terms of structure, nArgBP2 is composed of a conserved 
Sorbin homology domain (which was demonstrated to target proteins to lipid rafts) 
(Kimura et al., 2001), a zinc finger domain in the brain specific section of the protein 
and three SH3 domains near the C-terminus (Kawabe et al., 1999).  
Even with the above, much of the in vivo functions of nArgBP2 remain unknown. 
However, the association of nArgBP2 in a complex of PSD protein involved in other 
neuropsychiatric disorder (SAPAP3-OCD and Shank3-Autism) highlights a potential 
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role for this gene in related neuropsychiatric disorders. Importantly, the concept of a 
human phenome supports the functional analysis of genes and their association with 
similar disorders in a landscape of interrelated diseases which may originate from an 
overlapping molecular causation (Barabasi et al., 2011; Goh et al., 2007; Linghu et al., 
2009; Oti and Brunner, 2007; Oti et al., 2008; van Driel et al., 2006). This is particularly 
relevant to diseases which share common endophenotypes that may be brought about 
by functionally related genes which produce proteins that, at the cellular level, associate 
in a multiprotein complex (e.g. the complexes in the PSD) in the same pathway, or as 
part of the same subcellular organelle (Linghu et al., 2009; Oti and Brunner, 2007). This 
is particularly relevant for the study of nArgBP2 since the interaction of this protein with 
SAPAP3 and its enrichment at the PSD promotes an association of nArgBP2 with a 
cluster of proteins that are strongly implicated in the pathogenesis of several 
neuropsychiatric disorders.  
Finally, nArgBP2 is coded from the SORB2 gene which is present in 
chromosome 4q35, a region identified in BPD susceptibility. Therefore, the in vivo 
characterization and the exploration of the cellular roles of nArgBP2 are underexplored, 
at the same time as the potential involvement of this gene in neuropsychiatric disorders 
remains an interesting hypothesis. 
 
Autism Spectrum Disorders 
Overview of Autism Spectrum Disorders 
Leo Kanner (1943) and Hans Asperger (1944) independently identified and 
characterized the dysfunctional behavioral patterns present in autistic children. The 
term autism derives from the Greek word autós (meaning “self”) and was originally 
coined to describe how schizophrenic patients withdrew to self-generated fantasies. 
However, autism is now almost exclusively used to characterize the combination of the 
three main components in autism spectrum disorders (ASDs): 1) impairments in 
language and communication; 2) repetitive behaviors, interests or routines; and 3) 
deficits in social interaction and social behaviors (American Psychiatric Association, 
2000). Epidemiological studies estimate that approximately 1% of the human population 
displays some form of ASD (Baird et al., 2006; Bertrand et al., 2001; Chakrabarti and 
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Fombonne, 2005). Autism is also comorbid with other conditions and a large 
percentage of autistic individuals display intellectual disability (70%), sleep disturbances 
(50%), epilepsy (20-30%) or mood disorders (10-20%) (Geschwind, 2009; La Malfa et 
al., 2004; Leyfer et al., 2006; Tuchman and Rapin, 2002). ASDs are also highly 
heritable with reported concordance rates of 30% in dizygotic twins but 90% in 
monozygotic twins (Bailey et al., 1995; Rosenberg et al., 2009). Nevertheless, even 
though there is a very high degree of confidence for the genetic causation of autism, 
evidences suggest that paradoxically it is not necessarily inherited, but instead due in 
large percentage to de novo mutations (Beaudet, 2007). Moreover, recent work suggest 
that in 10-20% cases it is possible to identify the underlying genetic cause in ASD 
patients (Jacquemont et al., 2006; Sebat et al., 2007).  
In addition, there are a large numbers of genes associated with ASDs 
(Abrahams and Geschwind, 2008) and an emerging hypothesis centers on the fact that 
several of the known genes associated with ASDs code for proteins that are involved in 
synaptic function (van de Lagemaat and Grant, 2010; Zoghbi, 2003). Some of the most 
promising targets include the complex of trans-synaptic proteins formed by 
Neurexin/Neuroligin/PSD-95/SAPAP/Shank (Bourgeron, 2009; van de Lagemaat and 
Grant, 2010). Several of these genes have been linked to ASDs, including Shank2 and 
Shank3 (Berkel et al., 2010; Bonaglia et al., 2001; Bonaglia et al., 2006; Durand et al., 
2007; Gauthier et al., 2009; Pinto et al., 2010), SAPAP2 (Pinto et al., 2010), neurexin-1 
(Kim et al., 2008; Wisniowiecka-Kowalnik et al., 2010) and neuroligin-3 and -4 (Jamain 
et al., 2003). 
 
Neuroligins and Neurexins in Autism 
Neuroligins are cell-adhesion molecules located at the postsynaptic membrane 
and neurexins are their presynaptic binding partners (Shapiro et al., 2007). The 
neurexins are a family of proteins originally identified as one of the receptors for alpha-
latrotoxin (a component in black widow spider poison) (Ushkaryov et al., 1992). 
Neuroligin-1, in turn, was identified through its interaction with β-neurexins (Ichtchenko 
et al., 1995). Neurexins (1-3) genes are known to be alternatively spliced into 
thousands of different isoforms broadly subdivided into two groups, (1) α-neurexins, 
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characterized by the presence of a large extracellular portion containing six 
laminin/neurexin/sex-hormone-binding globulin (LNS) domains (Rudenko et al., 1999) 
and three interleaved epidermal growth factor (EGF)-like domains; and (2) β-neurexins, 
which only include the sixth LNS domain (Missler et al., 1998). Neuroligins, which are 
coded by 4 different genes, are endogenous neurexin ligands that express a signal 
sequence, a large extracellular domain functionally similar to an acetylcholinesterase 
domain, one  transmembrane region, and a C-terminal cytoplasmic domain which 
contains a PDZ recognition sequence (Ichtchenko et al., 1995; Missler et al., 1998). 
Postsynaptically, the PDZ recognition sequence interacts with downstream scaffolding 
proteins PSD-95 (Irie et al., 1997; Sudhof, 2008). 
Ectopic expression of neuroligin promotes postsynaptic differentiation in vitro 
(Chih et al., 2005) and similarly neurexins may induce the assembly of presynaptic 
terminals (Dean et al., 2003). The significant role played by these genes in the 
formation and regulation of synaptic function in the central nervous system is further 
enhanced by findings relating these genes to human disorders. Specifically, the 
identification of a missense mutation (R451C) in the Neuroligin-3 gene in two siblings 
afflicted by ASDs  and a frameshift inducing mutation in Neuroligin-4 present in two 
probands from a different family (Jamain et al., 2003). Moreover, one different group 
has also positively linked a mutation in neuroligin-4 with mental retardation and autism 
(Laumonnier et al., 2004).  
Importantly, mutant mice for neuroligins and neurexins have been used to 
model autism. Mice engineered to express the R451C mutation in the neuroligin-3 gene 
were shown to display impaired social behaviors, enhanced spatial learning and an in 
increase in inhibitory transmission. However, neuroligin-3 knockout mice did not 
manifest relevant autism-like behaviors, suggesting that a “gain-of-function” occurring 
with the amino acid substitution is the leading cause for the behavioral deficits (Tabuchi 
et al., 2007). Moreover, knockout mice for the neuroligin-4 gene do display behavioral 
deficits and abnormal vocalizations, suggesting phenotypical similarities to autism-like 
behaviors (Jamain et al., 2008). Murine genetic studies of the neurexin family of genes 
through targeted mutations are complicated due to the large number of isoforms. 
Nevertheless, converging evidences arrive from the studies in neurexin1α knockout 
mutant mice showing that these animals display increased repetitive grooming behavior 
and deficient nest building (a measure of sociability in mice) associated with a 
!
36!
functional decrease in glutamatergic synaptic strength in hippocampal neurons 
(Etherton et al., 2009).  
Phelan-McDermid Syndrome and Shank3 
Phelan-McDermid syndrome (PMS), also known as 22q13.3 microdeletion 
syndrome, is characterized by severe deficits in language delay, deficits in social 
behaviors and the presence of stereotypical behaviors. Several patients also display 
neonatal hypotonia, minor dysmorphic features and seizures (Phelan et al., 2001). 
Originally identified as a cytogenetic abnormality, several genes are eliminated with the 
deletion of the q13 tail of chromosome 22 (Prasad et al., 2000; Precht et al., 1998). 
From the multiple genes deleted in 22q13, Bonaglia and colleagues first proposed that 
the Shank3 gene deletion is the proximal cause for the origination of the main symptom 
in PMS (Bonaglia et al., 2001). Later, the same group also identified a recurrent 
breakpoint in the Shank3 gene which may lay at the basis for the chromosomal 
instability that leads to the 22q13 deletion (Bonaglia et al., 2006). A more refined view 
by gene sequencing has also confirmed that indeed Shank3 is the key gene 
responsible for the main neurological defects in PMS (Durand et al., 2007; Wilson et al., 
2003). Additionally, several mutations in Shank3 have been identified in ASD patients 
not clinically diagnosed with PMS, suggesting that Shank3 may indeed be responsible 
for a monogenic form of autism (Gauthier et al., 2009; Moessner et al., 2007). 
Shank family proteins (Shank1-3) are key elements at the postsynaptic density. 
Together with SAPAP proteins, Shank forms a dyadic interaction which organizes into a 
trans-synaptic complex of linearly interacting partners composed of 
Neurexin/Neuroligin/PSD-95/SAPAP/Shank (Bourgeron, 2009; van de Lagemaat and 
Grant, 2010) with several directly implicated in ASDs (Berkel et al., 2010; Jamain et al., 
2003; Kim et al., 2008; Pinto et al., 2010; Wisniowiecka-Kowalnik et al., 2010). 
At the protein level Shank genes give rise to several isoforms. The longest 
isoform of the Shank genes exhibit a multitude of protein-protein interaction domains, 
including ankyrin repeat domains, an SH3 domain, a PDZ domain, a proline-rich region 
and a SAM domain (Lim et al., 1999). Shank proteins are also a part of the PSD core 
(Naisbitt et al., 1999) and orchestrate a complex network with several other proteins, 
including α-Fodrin and Sharpin, which are binding partners at the N-terminal ankyrin 
repeat domain (Bockers et al., 2001; Lim et al., 2001). The SH3 domain of Shank binds 
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to Densin-180 (Quitsch et al., 2005).  The PDZ domain of Shank binds to the SAPAP-
PSD95-NMDA complex (Naisbitt et al., 1999) and the proline-rich region to Homer (Tu 
et al., 1999) and Cortactin (Du et al., 1998). Finally the SAM domain of Shank is known 
to undergo homo-oligomerization, which has been proposed to form a platform for the 
organization of the broader PSD network (Baron et al., 2006; Hayashi et al., 2009; 
Naisbitt et al., 1999). 
Converging evidences also arise from mouse models for Shank3 mutations. Our 
own work and from other groups have proposed Shank3 mutant mice as valid models 
for ASDs. Specifically,  we characterized two Shank3 knockout mouse lines  and found 
that mice with a genetic lesion in the PDZ domain of Shank3 (exons 13-16) exhibit 
severe impairments in social interaction and increased repetitive behaviors (Peca et al., 
2011). Together with other research groups we have shown that Shank3 mutation 
provide strong converging evidence that mutations in this gene lead to: a) impaired 
glutamatergic signaling; b) increased repetitive behaviors; c) dysfunction in social 
behaviors (Bangash et al., 2011; Bozdagi et al., 2010; Peca et al., 2011; Wang et al., 
2011). In our work we also found that Shank3 is the only Shank family member highly 
expressed in the striatum and that the cortico-striatal circuit is abnormal in these mice. 
The striatum is a brain region implicated both in OCD (repetitive actions)  (Graybiel, 
2008; Modell et al., 1989) and ASDs (response to social stimuli) (Scott-Van Zeeland et 
al., 2010), supporting a role for the basal ganglia as a focal point for the dysfunction in 
neurological circuits of autism (Damasio and Maurer, 1978). Interestingly, in humans 
there is also a link between social interaction and activity in this region. Specifically, 
ventral striatal activation is seen during functional imaging studies under a variety of 
rewarding social stimuli, such as observing beautiful faces, positive emotional 
expressions, images of maternal and romantic love and during the anticipation of a 
positive social feedback (Aharon et al., 2001; Bartels and Zeki, 2000; 2004; 
Rademacher et al., 2010; Spreckelmeyer et al., 2009). Conversely, this region is under-
activated in autistic patients in response to social stimuli (Scott-Van Zeeland et al., 
2010). Therefore, the Shank3 mutant mice provide a powerful tool to dissect the neural 
circuitry mechanisms underlying the abnormal behaviors relevant to human ASD and 
simultaneously a platform to test novel treatments.!!
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Objectives and Thesis Outline 
The study of neuropsychiatric disorders offers the possibility to explore to a 
higher degree of confidence what are the parameters for “normal” functioning of the 
brain and therefore convey a better understanding of this still mysterious organ. While 
we are gaining a better understanding of which brain regions may be responsible for 
discrete operant neuronal functions, conclusive evidences are often gained from the 
observation of lesions and studying behavioral output. This is perhaps best illustrated 
from the advances made in understanding functional compartmentalization thought the 
study of brain lesions (Blumenfeld, 2010) or more recently with targeted transcranial 
magnetic stimulation (Hallett, 2000). Nevertheless, tracing the direct influence of genes 
and gene mutations, their role in pathogenesis of electrophysiological, biochemical and 
ultimately behavioral deficits, is only possible using animal models.  
To this end, we started by studying the SAPAP3 gene (Appendix 1 (Welch et al., 
2007)) and identified a critical role played by this gene in the regulation of glutamatergic 
signaling, cortical striatal circuitry and mouse behavior. From this study we 
hypothesized that genes interacting with SAPAP3 could share the phenotypical 
landscape of neuropsychiatric disorders. We therefore defined the scope of our thesis 
to center on the role of other genes coding for proteins that are directly binding partners 
to SAPAP3. Specifically, we used a combination of database mining and bioinformatics 
to cross reference targets with their potential involvement in human genetic and 
neuropsychiatric disorders. This screen led us to focus on two particular genes: 
nArgBP2 and Shank3.  
We aimed at the characterization of the expression patterns of these genes in 
the mouse brain and performed disruptions by homologous recombination in ES cells to 
studied the biochemical, electrophysiological and behavioral consequences of 
disrupting Shank3 (Chapter 2) or nArgBP2 (Chapter 3 and 4) in vivo.!
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Chapter 2 
Shank3 mutant mice as a model for ASDs 
 
 
 
 
 
 
 
 
 
 
 
In the ensuing manuscript, Cátia Feliciano made the following contributions: 
Planned the research and designed the experiments 
Generated ES constructs, targeted ES cells and produced mutant mice 
Collected, analyzed and interpreted: 
Behavioral tests, in situ hybridization, biochemistry, cell fill data and electron 
microscopy 
Analyzed and interpreted: 
Golgi staining data 
Interpreted electrophysiology data 
Wrote the paper 
This work was publication with equal contribution from Peça, J. and Feliciano, C. 
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Chapter 3 
Characterization of nArgBP2 expression in the 
mouse brain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the ensuing work (manuscript in preparation), Cátia Feliciano made the following 
contributions: 
Designed experiments 
Produced DIG-RNA probes, anti-nArgBP2 antibody, performed in situs, protein 
stainings and characterized the anti-nArgBP2 antibody.     
Wrote the manuscript
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Abstract 
The postsynaptic density at glutamatergic synapses is a macromolecular 
complex essential for proper synaptic function. In the postsynaptic density, membrane-
bound receptors are functionally connected to the cellular cytoskeleton through multiple 
protein-protein layers of interactions. Several of the core synaptic scaffolding proteins 
have been characterized in recent years. The neuronal Arg binding protein-2 (nArgBP2) 
interacts with actin regulatory proteins and is a binding partner to the SAP90/PSD-95 
associated proteins (SAPAP) at the postsynaptic density. However, the expression 
pattern of nArgBP2 in the mouse brain and the relative contribution of nArgBP2 to total 
ArgBP2 expression in neuronal tissue remains unclear. Here, we present a detailed 
characterization of ArgBP2/nArgBP2 mRNA expression in the mouse brain and 
demonstrate that nArgBP2 is the main form expressed in the mouse forebrain while 
ArgBP2 forms are predominantly expressed in the cerebellum. Using an anti-nArgBP2 
specific antibody, we characterize protein expression across development and observe 
that nArgBP2 is enriched in discrete brain nuclei and at glutamatergic synapses. 
Introduction 
Excitatory glutamatergic transmission depends heavily on the correct assembly 
of the postsynaptic density (PSD) (Kennedy, 2000). The PSD is a macromolecular 
structure which clusters neurotransmitter receptors, signaling enzymes, adhesion 
complexes and scaffolding proteins all within a few nanometers of the postsynaptic 
membrane and in direct apposition to the presynaptic terminal (Sheng and 
Hoogenraad, 2007). Additionally, several proteins present at the PSD are known to 
associate with and regulate the synaptic actin cytoskeleton. This continuous link, from 
membrane bound receptor to the downstream cellular cytoskeleton is thought to be 
important for normal synaptic function and for the morphological changes occurring at 
dendritic spines (Dillon and Goda, 2005; Ehlers, 2002; Fischer et al., 2000). Also, 
substantial attention has been given to characterize and understand the role of core 
PSD scaffolding proteins, their molecular partners, expression patterns and synaptic 
role. Among others, these include the PSD-95-, the Shank- and the SAPAP-family of 
proteins (Bockers et al., 2004; Fukaya and Watanabe, 2000; Sala et al., 2001; Tu et al., 
1999; Welch et al., 2004).  
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ArgBP2 is a member of the Vinexin/Ponsin/ArgBP2 family of proteins which are 
thought to participate in signal transduction and in the regulation of the actin 
cytoskeleton (Kioka et al., 2002). ArgBP2 was originally identified as a phosphorylation 
target and binding partner to the Arg and Abl protein-tyrosine kinases (Wang et al., 
1997). The neuronal specific form of ArgBP2 (nArgBP2), was identified in a yeast two-
hybrid screen as a binding partner to SAPAP (Kawabe et al., 1999). In neuronal tissue, 
nArgBP2 is known to coordinate multiple mechanisms converging on the actin 
cytoskeleton and was shown to interact with actin regulatory proteins, suggesting it may 
lay downstream of SAPAP proteins in the PSD (Cestra et al., 2005; Ronty et al., 2005). 
At the cellular level, ArgBP2 is also present in cytoskeletal stress fibers and the cellular 
nucleus (Wang et al., 1997).  In terms of structure, both ArgBP2 and nArgBP2 feature a 
sorbin homology domain near the N-terminus and three SH3 domains at the C-
terminus. The sorbin homology domain is highly homologous to the sorbin peptide 
originally identified in the lumen of porcine duodenum (Vagne-Descroix et al., 1991). In 
humans, it is hypothesized that the sorbin peptide originates from an alternative splicing 
of the SORBS2 gene (ArgBP2) (Hand and Eiden, 2005). When present as part of a 
protein domain, the sorbin homology domain is thought to promote the targeting of 
proteins to lipid rafts (Kimura et al., 2001). The C-terminal SH3 domains have been 
characterized to mediate protein-protein interactions between ArgBP2/nArgBP2 and 
binding partners such as, Abl, Arg, Cbl, Pyk2, vinculin and afadin (Haglund et al., 2004; 
Kawabe et al., 1999; Soubeyran et al., 2003; Wang et al., 1997). Finally, nArgBP2 
contains a zinc finger domain in its neuronal-specific exon. This exon is highly 
conserved across mammalian species and gives rise to a 606 amino-acid portion of the 
protein (Kioka et al., 2002). 
As a first step towards understanding the in vivo role of nArgBP2 we have 
performed a sub-cellular and histological characterization of nArgBP2 in the mouse 
brain. To assess the presence of cellular transcripts for ArgBP2 and nArgBP2 we used 
in situ mRNA hybridization across serial sections the mouse brain. To evaluate the 
translation of the nArgBP2 mRNA products into functional protein, we generated an 
anti-nArgBP2 specific antibody and explored the brain and sub-cellular localization of 
nArgBP2 in the murine central nervous system. 
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Materials and Methods 
In situ hybridization 
ArgBP2 (nucleotide #3449-4239, ENSMUST00000135336, Sorbs2-004) and 
nArgBP2 (nucleotide #1856-2857, ENSMUST00000135336, Sorbs2-004) cDNA 
fragments were amplified by polymerase chain reaction (PCR) from an adult cDNA 
library and cloned into pBluescript II SK+ (Stratagene, La Jolla, CA, USA). Plasmids 
were linearized with restriction enzymes (NotI or XhoI, New England BioLabs, Ipswich, 
MA, USA) that generated 5’ overhangs. The transcription reactions and Digoxigenin 
(DIG)-labeling of RNA probes were performed using the MAXIscript in vitro RNA 
synthesis kit (Ambion, Austin, TX, USA). For both ArgBP2 and nArgBP2, the sense 
strands were generated by T7 RNA polymerase and the antisense strands by T3 RNA 
polymerase. Quantification of DIG-labeled probes was done by dot blotting and probing 
with alkaline phosphatase-conjugated anti-DIG antibody, using a DIG-RNA standard 
(Roche, Indianapolis, IN, USA). P21 and adult (3 months-old) mice were deeply 
anesthetized with isofluorane, and perfused with PBS followed by 4% 
paraformaldehyde/PBS (PFA, Electron Microscopy Sciences, Hatfield, PA, USA). 
Brains were dissected, embedded in OCT compound (TissueTek, Torrance, CA, USA) 
and frozen in ethanol/dry ice slush. Blocks were mounted for coronal and sagittal 
planes and 20 µm thick sections were cut on a Leica CM1850 cryostat (Leica 
Microsystems, Richmond Hill, Ontario, Canada). Brain sections were collected onto 
Superfrost Plus slides (Fisher Scientific, Swanee, GA, USA) and air dried at room 
temperature (RT) for 1 hour. The sections were then fixed in 4% (PFA) in PBS for 10 
minutes at RT, washed 3 times with PBS for 3 minutes each, acetylated for 10 minutes 
at RT in TEA buffer (4 ml triethanolamine and 0.525 ml 12.1 M HCl were added to 295 
ml H2O and stirred; 0.75 ml acetic anhydride was added just before sections were 
immersed) and again washed 3 times with PBS for 3 minutes each. For 
prehybridization, sections were incubated with hybridization buffer (50% formamide 
[Sigma, St. Luis, MO, USA], 5X SSC [750 mM NaCl, 75 mM Na-Citrate], 5X Denhardt’s 
solution [Sigma], 250 µg/ml yeast tRNA [Roche], 500 µg/ml salmon sperm DNA 
[Sigma], 50 µg/ml heparin [Sigma] in DEPC-dH2O for 1 hour at RT. DIG-labeled RNA 
probes were diluted in hybridization solution to a working concentration of 1000 ng/ml, 
heated at 70°C for 10 minutes and chilled on ice.  The prehybridization solution was 
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removed and hybridization mixture was added to the sections. The sections were 
covered with parafilm. The hybridization was done overnight at 68°C in a humidified 
chamber containing 50% formamide/2XSSC. After hybridization, parafilm was removed 
by dipping the sections in 2XSSC at RT. Sections were washed 4 times in 0.2XSSC at 
68°C for 3 hours, then adjusted to RT in 0.2XSSC for 5 minutes and washed 2X5 
minutes with TBS (150 mM NaCl, 10 mM Tris-HCl, pH 7.4). For immunological 
detection, sections were incubated with blocking buffer (10% normal sheep serum, 
0.2% blocking reagent [Roche]) for 1 hour at RT, followed by incubation with alkaline 
phosphatase-conjugated anti-DIG antibody (1:2000 in blocking buffer) overnight at 4°C. 
Sections were washed 4X10 minutes with TBS and incubated with color detection 
buffer (100 mM NaCl, 50 mM MgCl2, 0,24 mg/ml levamisole, 100 mM Tris-HCl, pH 9.5) 
for 5 minutes. The color reaction was performed in the presence of nitroblue tetrazolium 
(NBT; 0.35 mg/ml) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP; 0.175 mg/ml) in 
detection buffer at RT in the dark. Incubation depended on how quickly signal from the 
antisense probe appears versus background signal in the sense probe. Sections were 
then washed in TBS, water and then mounted with 90% glycerol/H2O. Images were 
collected on a Zeiss Axioskop 2 Plus (Carl Zeiss, Thornwood, NY, USA) with a Zeiss 
Neofluar 4X objective using a Zeiss Axiocam digital camera (Carl Zeiss). Images were 
assembled and processed using Adobe Photoshop (Adobe Systems, San Jose, CA, 
USA). 
Antibody production and purification 
The sequence of the mouse nArgBP2 gene (ENSMUST00000135336, Sorbs2-
004) was used to design PCR primer sets to amplify a region unique and of suitable 
antigenicity, encoding a 201 amino acids region (404-604, ENSMUSP00000114286, 
SORBS2-004), corresponding to the brain specific exon of SORBS2. The nArgBP2 
selected region was amplified by PCR from an adult cDNA library using Pfu Turbo DNA 
Polymerase (Stratagene, La Jolla, CA, USA) and cloned in frame into the bacterial 
expression vector pET-23b (+). A histidine-tagged fusion protein (His-nArgBP2404-604) 
was produced with the pET overexpression system (Novagen, Madison, WI, USA). 
Transformed BL21(DE3) bacteria were grown, lysed and separated into soluble and 
insoluble fractions. Isopropylthio-β-galactoside (IPTG) induced bacterial expression of 
the fusion protein. To determine the relative solubility of the fusion protein, both 
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fractions were run out on SDS-PAGE and stained with Coomassie blue. The fusion 
protein His-nArgBP2404-604 was insoluble. The preparation of the insoluble fusion protein 
was done under denaturing conditions, by solubilization of the inclusion bodies with 6 M 
Guanidine hydrochloride (Guanidine-HCl, Sigma) and purification on a HisBind Quick 
Column (Novagen), with all the solutions containing 6 M Guanidine-HCl. The Quick 
column eluates were dialyzed against 6 washes of 4L PBS/0.02% sodium azide at 4°C 
(6X 12 hours) and collected at the end of the dialysis. The histidine column-purified 
fusion proteins were run out via SDS-PAGE and the gel was stained using 0.05% 
Coomassie stain in H2O. After several washes with H2O, the band corresponding to the 
size of the fusion protein was cut from the gel and sent to Washington Biotechnology 
(Baltimore, MD, USA). Approximately 2.2 mg of fusion protein was sent. Polyclonal 
antibodies were prepared by immunizing two rabbits with the fusion protein present in 
the polyacrylamide gel material. Upon receipt of the serum bleeds (nArgBP2-A and 
nArgBP2-B, corresponding to each immunized rabbit), the antibodies were affinity-
purified. More fusion protein (approximately 2 mg) was generated and purified as 
above. The band was excised from the gel and minced, and the fusion protein was 
electroeluted (model 422 Electro-Eluter, Bio-Rad, Hercules, CA, USA) and then 
dialyzed against coupling buffer (CB) solution (0.1 M NaHCO3, 0.1 M NaCl, pH 8.4) for 
4 times with change of buffer every 12 hours, to remove Tris-containing buffer. The 
fusion protein was collected and concentrated to a final volume of 0.5 ml using a 
Centriprep column (Ultracel YM-3 membrane of 3,000 Nominal Molecular Weight Limit, 
Millipore, Bedford, MA, USA). 0.5 ml of 2X CB and then 4 ml CB with 1.25% SDS were 
added (the final concentration of SDS is 1%). 20 µl were kept as control for 
determination of protein concentration before coupling. 0.2 g of cyanogen bromide-
activated Sepharose 4B beads (Sigma) were weighed out and allowed to swell on ice 
for 1 hour with 50 ml of 1 mM HCl. After shaking, the bead-acid gel was poured into an 
empty HisBind quick column and washed with 10 ml of cold water 5 times. The column 
was then washed with 5 ml of CB and the fusion protein was immediately added. The 
column was stopped at the top and bottom and placed sideways on a rotator for 2 
hours at room temperature to allow the fusion protein to couple with the beads. The 
protein/SDS solution was drained into a tube and saved for determination of coupling 
efficiency. The column was washed 5 times with CB and then unreacted groups were 
blocked overnight at 4°C with 0.2 M glycine, pH 8.0. The column was then washed 5 
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times alternatively with CB and acetate buffer (0.1 M acetic acid, 0.1 M NaCl, pH 4.0) 
and then with 20 ml of PBS/0.02% sodium azide. The gel was transferred to a polyprep 
column (Bio-Rad) with 5 ml PBS/0.02% sodium azide. The sealed column was kept at 
4°C until antibody purification. Protein solutions before and after coupling were 
compared by reading OD280. Protein concentration was also determined using BCA 
protein assay (Pierce Thermo Scientific, Rockford, IL, USA). Serum from the 
immunized rabbits was thawed and first purified by ammonium sulfate precipitation. 
Briefly, ammonium sulfate was slowly added to serum while stirring until 50% volume. 
The mixture was stirred overnight at 4°C and then centrifuged at 5,000 g for 30 
minutes. The pellet was resuspended in 0.4 volumes of the starting serum volume and 
filtered (0.2 µm). The filtrate was collected and dialyzed versus three changes of 
PBS/0.02% sodium azide overnight at 4°C. Just prior to column purification, the column 
was washed with 10 bed volumes of 10 mM Tris (pH 7.5), followed by 10 bed volumes 
of 100 mM glycine (pH 2.2) and 10 bed volumes of 10 mM Tris buffer (pH 8.8). When 
the last bed volume was confirmed with litmus paper to be at pH 8.8, 10 bed volumes of 
100 mM triethylamine (pH 11.5, prepared fresh) were added and then the column was 
washed again with 10 mM Tris Buffer (pH 7.5) until the pH reached 7.5. Serum was 
passed through the column 3 times, followed by 30 bed volumes of 10 mM Tris (pH 7.5) 
and 30 bed volumes of 10 mM Tris/500 mM NaCl (pH 7.5). Acid-sensitive antibody-
antigen interactions were broken with 10 bed volumes of 100 mM glycine (pH 2.2) and 
eluted into a tube containing 30% of the elution volume of 1 M Tris (pH 8.0). The 
column was then washed with 10 mM Tris (pH 8.8) until a pH of 8.8 was recorded at the 
outflow. The antibodies bound by base-sensitive interactions were eluted by passing 10 
bed volumes of 100 mM triethylamine (pH 11.5, prepared fresh) through the column. 
The antibodies were collected in a tube containing 15% of the elution volume of 1 M tris 
(pH 6.0). Antibody fractions were combined, dialyzed against PBS/0.02% sodium azide 
(4X 12 hours) and collected. Antibody concentration was determined by BCA protein 
assay (Pierce Thermo Scientific) and the antibody was diluted to 250 µg/ml in 0.2% 
bovine serum albumin (BSA, Sigma)/PBS. 
Evaluation of antibody specificity 
In order to confirm that the rabbit polyclonal antibody generated is able to 
recognize the nArgBP2 protein, HEK cells were plated in 6-well plates and transfected 
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with a total of 2 µg DNA and 2 µl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
per well. 36 hours after transfection, cells were lysed with SDS-PAGE loading buffer. 
nArgBP2-A and nArgBP2-B rabbit polyclonal antibodies (1:1000, incubation overnight 
at 4°C) were tested on lysates from HEK cells that were either non-transfected, 
transfected with pCINeo-Myc-nArgBP2 or empty vector (control). Secondary antibody 
Peroxidase-conjugated Donkey Anti-Rabbit IgG (Jackson ImmunoResearch Lab, West 
Grove, PA, USA) was added at 1:20000 dilution and incubated 4 hours at RT. Western 
development was perform by incubating the membrane with ECL Plus (Amersham) and 
imaged in a STORM 860 (GE Healthcare). Only nArgBP2-A recognized a specific band. 
Fluorescent immunohistochemistry 
P14, P21 and adult (3 months-old) mice were deeply anesthetized with 
isofluorane and perfused with Lactated Ringer’s solution followed by 4% PFA (in PBS). 
Brains were dissected and post-fixed overnight in the same solution. 50 µm sagittal 
sections were cut using a vibratome (Pelco 102, Ted Pella, Redding, CA). Sections 
were washed 3X 5 minutes in PBS and then blocked for 1 hour with blocking buffer (5% 
normal goat serum [Sigma], 2% BSA [Sigma] and 0.2% triton X-100 (Sigma) in PBS). 
Sections were incubated with primary antibody (nArgBP2-A, 1:100) overnight at 4°C, 
washed 3X 20 minutes in PBS and then incubated for 4 hours with Alexa Fluor 488 
goat anti-rabbit secondary antibody (Invitrogen/Molecular Probes, Carlsbad, CA, USA) 
diluted 1:1000 in blocking solution. Following secondary antibody incubation, sections 
were washed 3X 20 minutes in PBS and mounted with PPD solution (1mg/mL para-
phenylenediamine [ICN, Aurora, OH] in 90% glycerol/PBS). For P0 and P7 brains, 10 
µm sections were cut from freshly frozen brains on a cryostat at -19°C and mounted on 
gelatin-coated Superfrost Microscope slides (Fisher Scientific). The sections were fixed 
in 4% (PFA) in PBS for 10 minutes at RT. From this step on, the procedure is similar as 
above. Images were collected on a Zeiss Axioskop 2 Plus (Carl Zeiss, Thornwood, NY, 
USA) with a Zeiss Neofluar 4X objective using a Zeiss Axiocam digital camera (Carl 
Zeiss). Images were assembled and processed using Adobe Photoshop (Adobe 
Systems, San Jose, CA, USA).  
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Neuron Culture and Fluorescent immunocytochemistry 
Hippocampal neurons from P2 mice were co-cultured with rat astrocytes in a 
“sandwich” format at the density of 12,500 cells/cm2 as described previously (Kaech 
and Banker, 2006). Neurons were fixed in 4% PFA, 4% sucrose in PBS solution for 20 
minutes at 4°C and subsequently permeabilized with 0.2% Triton X-100 in PBS for 10 
minutes at 4°C. Neurons were then blocked with 5% BSA, 15% normal goat serum in 
PBS solution for 1 hour at RT. Primary antibodies diluted in blocking buffer were added 
and incubated overnight at 4°C. Neurons were then washed four times with blocking 
buffer for 5 minutes each. Secondary antibodies (Invitrogen/Molecular Probes) were 
diluted 1:1000 in blocking buffer and incubated with neurons for 1 hour at RT. 
Coverslips were then washed four times with PBS, one time with water and then 
mounted on glass slides using ProLong Gold Antifade Reagent (Invitrogen). The 
primary antibodies were diluted in blocking buffer and used at the following dilutions: 
nArgBP2-A rabbit polyclonal, 1:200; anti-PSD-95 mouse monoclonal IgG2a (clone 6G6-
1C9, Thermo Scientific), 1:400; anti-synapsin 1/2 guinea pig polyclonal antiserum 
(Synaptic Systems, Göttingen, Germany), 1:1000; anti-gephyrin mouse monoclonal, 
hybridoma supernatant from mAb7a cell line (Synaptic Systems), 1:800. These primary 
antibodies were recognized by the following secondary antibodies: goat anti-rabbit 
Alexa488, goat anti-mouse Alexa555 and goat anti-guinea pig Alexa647.  
Images were captured by using Olympus Fluoview FV1000 confocal microscope 
with 60x objective (UPlanSApo, 1.35 oil) at the 1024x1024 pixel resolution. Images 
were acquired as a Z-stack with 0.50 um interval for a total depth of 2 µm. Maximum 
intensity projections were then formed from the Z-stacks.  
 Postsynaptic density isolation 
The PSD fraction of forebrain was prepared as described (Welch et al., 2004; 
Ehlers, 2003) with slight alterations. All the steps in the protocol are done at 4°C. 
Approximately 200 mg of mouse forebrain was homogenized in 3 ml of a solution 
containing HEPES-buffered sucrose (HBS, 4 mM HEPES, 0.32 M sucrose, pH 7.4) with 
a protease inhibitor cocktail (Roche, 11873580001) and two phosphatase inhibitor 
cocktails (Sigma, P2850, P5726) using a motor driven glass-teflon homogenizer for 30 
strokes at ± 900 rpm. The homogenates were then centrifuged at 700 g for 15 minutes 
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to remove the pelleted nuclear fraction (P1). The supernatant was collected (S1) and 
this step was repeated, collecting the supernatant again (S2). This fraction corresponds 
to the Brain Lysate. The resulting supernatant (S1) was centrifuged at 18,000 g for 15 
minutes to yield a pellet corresponding to the crude synaptosomal membrane (P2). The 
pellet was resuspended in 1 ml HBS and centrifuged at 18,000 g for 15 minutes to yield 
the pelleted washed crude synaptosomal fraction (P2’). The pellet was then lysed by 
osmotic shock by adding 3 ml of cold 4 mM HEPES, pH 7.4 and by applying 8 strokes 
of glass-teflon homogenizer to pooled samples followed by mixing in an orbital shaker 
for 1 hour. Samples were centrifuged at 25,000 g for 20 minutes to yield a supernatant 
(crude synaptic vesicle fraction, S3) and a pellet (lysed synaptosomal membrane 
fraction, P3). P3 was then well resuspended in 100 µl of HBS. P3 was then layered on 
top of a discontinuous sucrose gradient of 0.8, 1.0 and 1.2 M (500 µl each layer) and 
centrifuged at 150,000 g for 2 hours. The synaptic plasma membrane (SPM) fraction 
was obtained by extracting the layer between the 1.0 and 1.2 M sucrose gradient, 
diluted by adding 2.5 volumes of 4 mM HEPES, pH 7.4 (with protease and phosphatase 
inhibitors) and pelleted by centrifugation at 150,000 g for 30 minutes. Pellet (SPM) was 
resuspended in 500 µl of 50 mM HEPES, 2 mM EDTA, pH 7.4 (with protease and 
phosphatase inhibitors) and Triton X-100 was added to 0.5% and mixed. After rotating 
at 4°C for 15 minutes, samples were centrifuged at 32,000 g for 20 minutes to yield the 
PSD-1T fraction (pellet). PSD-1T was resuspended in 500 µl of 50 mM HEPES, 2 mM 
EDTA, pH 7.4 (with protease and phosphatase inhibitors), Triton X-100 was added to 
0.5% and mixed. After rotating at 4°C for 15 minutes, samples were centrifuged at 
200,000 g for 20 minutes to yield the PSD-2T fraction (pellet). PSD-2T was recovered is 
100 µl of 50 mM HEPES, 2 mM EDTA, pH 7.4 (with protease and phosphatase 
inhibitors). Protein concentration was determined using BCA protein assay (Pierce 
Thermo Scientific). 
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Results 
Expression of ArgBP2 and nArgBP2 in the mouse brain 
To assess the expression of the different ArgBP2 isoforms by mRNA in situ 
hybridization, we designed one probe for a region in common among ArgBP2 mRNA 
isoforms in order to detect the expression of both neuronal and non-neuronal forms, 
and a second probe to specifically identify the neuronal specific form - nArgBP2- . This 
was achieved by taking advantage of the unique region expressed in this isoform. 
Bioinformatic analysis reveals that there is no unique region exclusively expressed in 
non-neuronal forms of ArgBP2; therefore, a “non-neuronal” probe could not be 
generated. To comparatively assess mRNA expression in the adult mouse brain we 
collected serial sections from adult mice and performed probe incubations and signal 
development in parallel for both probes. In situ mRNA hybridization of adult mouse 
sections revealed that ArgBP2 is highly expressed in several brain regions (Fig. 1A). 
Expression of nArgBP2 was largely equivalent and most areas displayed a signal 
intensity comparable to that of the common region probe (Fig. 1E).  
ArgBP2 labeling in the olfactory bulb was abundant in glomerular cell layer (Gl) 
and mitral cell layer (ML) (Fig. 1B). Labeling for nArgBP2 in the same regions was 
present but the signal intensity was slightly less intense when compared to the probe 
for the common region (Fig. 1F). High levels of expression of ArgBP2/nArgBP2 were 
seen in cortical layers II/III and VI, but only few cells in cortical layer V express these 
transcripts (Fig. 1C, G). Very high levels of expression of ArgBP2/nArgBP2 are present 
in the hippocampal formation, including CA1 and CA3 pyramidal neurons and dentate 
gyrus granule cells (Fig. 1D, H). Both probes detect high levels of mRNA expression in 
the striatum. In the thalamus, sparse but strong labeling was observed for individual 
cells using both probes (Fig. 1A, E). Differential expression was observed between the 
two probes in the cerebellum. In this region, ArgBP2 but not ArgBP2 was strongly 
expressed in the granule cell layer (gcl) (Fig. 1A, E). Dendritic targeting of 
ArgBP2/nArgBP2 mRNA was not observed, since no signal was detected in cortical 
layer I or in the molecular layer in the hippocampal formation. 
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nArgBP2 is the main neuronal form in the mouse brain with the exception of the 
cerebellum 
After observing largely similar expression pattern between ArgBP2 and 
nArgBP2 probes we postulated that nArgBP2 would be the main isoform in the brain 
contributing to the overall ArgBP2 signal. To test this, we used serial sections to assess 
the differential expression of ArgBP2/nArgBP2 in P21 mice (Fig. 2A). A qualitative 
assessment of these differences was achieved by comparing sections from the same 
mouse and digitally subtracting the signal of nArgBP2 from the signal of total ArgBP2 
(Fig. 2B) (total ArgBP2 minus nArgBP2). This manipulation estimates the signal 
intensity and regional differential expression of non-neuronal forms of ArgBP2. We 
observed that the expression of non-neuronal ArgBP2 is mostly concentrated in the 
mouse cerebellum ganglion cell layer. In all other brain regions, nArgBP2 is the 
predominant form (Fig. 2B). 
Detailed mRNA expression of nArgBP2 across serial mouse brain sections 
After determining that nArgBP2 is the main form expressed in the mouse brain 
we performed a detailed in situ mRNA across coronal and sagittal sections to determine 
expression in discrete nuclei (Fig. 3). We found that expression in the amygdala was 
abundant and at high expression levels; including in the anterior (BLA) to posterior 
(BLP) basolateral and basomedial amygdaloid nucleus (BMP) (Fig. 3A, D, E). 
Expression of nArgBP2 was also found in the habenula (Hb) and some sparse 
expression was found in the hypothalamic nuclei (MH) (Fig. 3B, F, G). Finally, strong 
labeling was observed in the dorsal part of the lateral septal nucleus, dorsal (LSD) (Fig. 
3H) and the piriform cortex (Pir) (Fig. 3I).  
Characterization of an anti-nArgBP2 specific antibody 
nArgBP2 is unique due to the inclusion of a single exon which codes for a 606 
amino acid section of the protein. We produced a specific antibody designed to 
recognize nArgBP2 through the use of a recombinant antigen consisting of the first 201 
amino acids of this region (Fig. 4A). Bioinformatic analysis revealed that this protein 
sequence displays high levels of antigenicity and does not share homology with other 
known proteins, with the exception of the nArgBP2 mammalian orthologous. To assess 
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specificity, the antibody was tested against the lysate of HEK cells transfected with a 
nArgBP2 expression vector (Fig. 4B). The antibody was also used to recognize 
nArgBP2 after overexpression in high density hippocampal neuron cultures at DIV 8 
(Fig. 4C). After overexpression, nArgBP2 was found in the cell body, nucleus, dendritic 
processes and spines of transfected neurons (Fig. 4C). Endogenous protein expression 
was also observed in nearby non-transfected neurons (Fig. 4C – star). To assess the 
recognition of endogenous protein in brain tissue we performed western blotting in 
samples of brain lysate, synaptosomal plasma membrane (SPM) and twice washed 
Triton X-100-extracted postsynaptic density (PSD-2T) fraction.  
A single protein band of approximately 180kD was detected across all fractions. 
The apparent molecular weight of this band is consistent with predicted amino acid 
composition for nArgBP2 (Fig. 4D). We also observed an enrichment of nArgBP2 
across the PSD purification gradient (Fig. 4D). Together, these results demonstrate a 
high specificity for the anti-nArgBP2 antibody and confirm the enrichment of nArgBP2 at 
the PSD. 
Localization and enrichment of nArgBP2 protein in the mouse brain 
Using the anti-nArgBP2 specific antibody, we next characterized the expression 
pattern of nArgBP2 at the protein level in the mouse brain across five developmental 
time-points: P0, P7, P14, P21 and 3 months-old (Fig. 5 and Fig. 6). Neonatal (P0) 
expression of nArgBP2 was mostly restricted to the dentate gyrus with some low-level 
expression in the striatum (Fig. 5A). At P7, there was strong expression in the 
hippocampus, the striatum and olfactory bulb, but low levels of expression of nArgBP2 
in cortical layers (Fig. 5B). In the cortex, expression was mostly prevalent in layer IV 
cells. Expression in layers I, II/III and VI was low at P7.  Notably, layer V cortical 
neurons and the cerebellum region do not express significant levels of nArgBP2, 
confirming the results observed from mRNA in situ hybridization. At P14 and P21, 
nArgBP2 was strongly detected in the hippocampal formation, the striatum and cortical 
layers I, II/III, IV and VI (Fig. 5C-D). After P14, moderate levels of expression can also 
be found in several thalamic nuclei (Fig. 5D). We also examined the expression of 
nArgBP2 across parasagittal and coronal section in adult mice to examine enrichment 
in specific nuclei (Fig. 6A-B). In the olfactory bulb, low levels of expression were 
observed in glomeruli (Fig. 6C) and in the accessory olfactory bulb (AOB) (Fig. 6A). In 
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the adult brain, highest levels of expression were present in cortical layers II/III and IV 
(Fig. 6D), the striatum (Fig. 6E), the amygdala (Fig. 6F), in the habenula (Hb) (Fig. 6G) 
and in the superior paraolivary nucleus (SPON) (Fig. 6H). In the striatum, nArgBP2 is 
particularly enriched in sparse, patch-like islands reminiscent of striosomes (St) 
(Graybiel, 1984). In the thalamus, low levels of expression were observed in the ventral 
thalamic nuclei (VTN) (Fig. 6I). Low levels of expression were found in the medial 
hypothalamus (MH), but high expression levels in the arcuate hypothalamic nucleus 
(Arc) (Fig. 6J). Finally, one distinct pattern was observed in the strong labeling of 
nArgBP2 at the outer molecular layer of the dentate gyrus (Fig. 6K).  
nArgBP2 is present in excitatory but not inhibitory synapses 
We next investigated if, at the cellular level, nArgBP2 localizes to both excitatory 
and inhibitory synapses. Using low-density DIV 14 hippocampal neuron cultures we 
performed a triple staining for endogenous nArgBP2, gephyrin and the ubiquitous 
presynaptic marker synapsin (Fig. 7A-D). Gephyrin is a component of the postsynaptic 
network in glycinergic and gabaergic synapses (Feng et al., 1998; Jacob et al., 2005).  
We observed that nArgBP2 does not co-localize with gephyrin (Fig. 7A’-D’). To assess 
if nArgBP2 is present at excitatory synapses, we performed a triple staining for 
nArgBP2, the excitatory postsynaptic marker PSD-95 and synapsin (Fig. 8A-D). We 
observed that nArgBP2 strongly co-localizes with PSD-95 (Fig. 8A’-D’). Moreover, a 
high magnification analysis, reveals the expected apposition between synapsin and 
PSD-95 and a superimposition of the nArgBP2 signal on PSD-95 puncta (Fig. 8A’’-D’’). 
This result suggests that nArgBP2 is localized to the postsynaptic compartment but is 
concentrated distally to PSD-95 and the postsynaptic membrane (Fig. 8E). Core PSD 
proteins, such PSD-95, are usually localized within a few nanometer of the postsynaptic 
cleft (Petersen et al., 2003). At the same time, the more distal localization of nArgBP2 is 
consistent with its role in interacting with actin regulatory proteins at the interface of the 
PSD and the actin cytoskeleton. 
Discussion 
In this study we have presented a detailed characterization on the expression of 
ArgBP2 in the mouse brain. We observed that nArgBP2 is the main ArgBP2 isoform 
present in the central nervous system and that there is a differential expression of this 
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isoform across development. In the adult brain, nArgBP2 mRNA and protein are 
specifically enriched in discrete regions and nuclei, such as the habenula, striasomes 
and the outer molecular layer of the dentate gyrus. We also observed that nArgBP2 is 
specifically localized to glutamatergic synapses but not to inhibitory gabaergic or 
glycinergic synapses.  
While the functional role of the protein section coded by the brain specific exon 
is still unknown, this section is selectively included in nArgBP2 transcripts. We also 
found that nArgBP2 is not significantly expressed in the cerebellum as whole. 
Interestingly, at the synaptic level it is known that there are striking differences in the 
composition in cerebellar PSD proteins when comparing to forebrain PSDs. Examples 
include CAMKII and Shank3, which among other PSD proteins, are known to be 
differentially expressed between these two anatomical regions (Cheng et al., 2006; 
Miller and Kennedy, 1985). Interestingly, the Shank family of proteins and nArgBP2 
share other similarities. Both are large proteins with multiple protein-protein interaction 
domains, both interact with the SAPAP family of proteins (Kawabe et al., 1999; Naisbitt 
et al., 1999) and both mediate the interaction between core PSD proteins and actin 
regulatory elements (Bockers et al., 2001; Cestra et al., 2005; Park et al., 2003; Ronty 
et al., 2005). Recently, we have investigated the role these two key proteins in the PSD 
complex where nArgBP2 is inserted. Characterization of SAPAP3 and Shank3 
uncovered an important role for these scaffolding proteins in synaptic function and 
behavior (Peca et al., 2011; Welch et al., 2007; Welch et al., 2004). Therefore, it will be 
important to understand if nArgBP2, a member of the Shank3-SAPAP3 complex, may 
also play a role in the regulation of glutamatergic synapses. Here, we presented a first 
step into better understanding the role of nArgBP2 in the murine brain though its 
neuroanatomical characterization.   
One interesting finding in this characterization work is the observation of a 
strong local enrichment of nArgBP2 in the dentate gyrus. Afferent enervation to the 
dentate gyrus segregates mainly into the lateral perforant pathway from entorhinal 
cortical neurons which synapses on dendrites extending into the outer molecular layer, 
and anterior commissure fibers which make connections with proximal synapses in the 
inner molecular layer of dentate granule cells (Forster et al., 2006). The enrichment of 
nArgBP2 at the outer molecular layer in the dentate gyrus could signify either 
enrichment in presynaptic terminals from the lateral perforant pathway or a differential 
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postsynaptic enrichment in granule cells distal synapses. Evidences supporting the 
latter come from the observation that nArgBP2 is enriched in postsynaptic density 
fractions and its co-localization with PSD-95 but not with synapsin. Additionally, at P0 
ArgBP2 is highly expressed in the dentate gyrus, but virtually absent from other brain 
regions, including the entorhinal cortex, suggesting again that this enrichment may 
arise from a postsynaptic mechanism. Notably, the actin dynamics in the dentate gyrus 
molecular layer are known to work independently between layers and selectively 
respond to electrical stimuli originating in different excitatory pathway (Fukazawa et al., 
2003). Therefore, it is interesting to speculate that the enrichment of nArgBP2 may 
mediate the segregation of layer specific postsynaptic mechanisms. 
The demonstration that nArgBP2 is not present in inhibitory synapses further 
supports evidences that inhibitory postsynaptic protein networks specialization are 
profoundly different in their biochemical composition when compared to PSD network at 
excitatory synapses (Kneussel and Betz, 2000; Kneussel and Loebrich, 2007; Ryan 
and Grant, 2009; Sheng and Hoogenraad, 2007). Interestingly, there are increasing 
evidences pointing to the role of multiple PSD proteins in synaptic dysfunction and 
disease. Multiple lines of evidences have linked dysfunction in PSD proteins with neural 
disorders. It is estimated that from the over 1000 different PSD proteins, a large number 
of these are associated with one or more of 130 neurological phenotypes (Bayes et al., 
2011). Interestingly, in silico and meta-analysis studies have shown that proteins known 
to play a role in disease afford its biochemical interaction partners a higher probability 
of also playing a pathological role (Barabasi et al., 2011; Goh et al., 2007; Linghu et al., 
2009; Oti et al., 2008). Shank3 plays a key role in the development of autism spectrum 
disorders and also schizophrenia (Durand et al., 2007; Gauthier et al., 2010; Peca et 
al., 2011). Similarly, SAPAP3 also plays an important role in the normal maturation of 
glutamatergic PSDs and mutations in this gene may be responsible for a susceptibility 
to obsessive-compulsive behaviors (Bienvenu et al., 2009; Boardman et al., 2010; 
Welch et al., 2007; Zuchner et al., 2009). Therefore, studies aimed at understanding the 
in vivo role of nArgBP2 and a possible link to human disorders are critical to address. 
Our present work established a detailed characterization of this protein and identifies 
the brain regions where nArgBP2 may exert its endogenous function. 
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Figure Legends 
Figure 1 – Expression of ArgBP2 and nArgBP2 mRNA in the adult mouse brain. A, In 
situ mRNA hybridization for ArgBP2 transcripts in a parasagittal whole brain section 
from a 3 month old C57/B6 mouse. B, The olfactory bulb displays ArgBP2 labeling in 
the glomeruli layer and mitral cell layer. C, High magnification image from cortical layers 
demonstrate a dense labeling in layers II/III, IV and VI, but a sparse labeling in layer V. 
D Hippocampal formation presents strong labeling for ArgBP2 in cell bodies of CA1, 
CA3 and dentate gyrus granule cell layer. E, In situ hybridization for nArgBP2 mRNA in 
a parasagittal whole brain section from a 3 month old C57/B6 mouse. F, Olfactory bulb 
displays some nArgBP2 labeling in the glomeruli layer and mitral cell layer. G, Cortical 
layers present a dense labeling for nArgBP2 in layers II/III, IV and VI, but a sparse 
labeling in layer V. H, Hippocampal formation is strongly labeled for nArgBP2 in cell 
bodies of CA1, CA3 dentate gyrus granule cell layer. Scale bar, 1mm for A and E, and 
300 µm for B-D and F-H. For abbreviations see list. 
Figure 2 – nArgBP2 is the main ArgBP2 form in the mouse brain with the exception of 
the cerebellum. A, Sections from a P21 brain were used to detect ArgBP2 and 
nArgBP2. B, Digital subtraction of ArgBP2 signal minus nArgBP2 signal reveals that 
non-neuronal ArgBP2 is mainly expressed in the cerebellum (B) (arrow). In remain 
regions, nArgBP2 is the dominant form. Images were pixelated to smooth cellular level 
differences.   
Figure 3 – Expression of nArgBP2 transcripts in discrete brain nuclei in the adult 
mouse brain. A-C, nArgBP2 in parasagittal section (A) and coronal sections (B-C). D-I 
nArgBP2 is strongly expressed in the amygdala, including the anterior basolateral 
amygdaloid nucleus (BLA) and the posterior basolateral amygdaloid nucleus (BLP) (D-
E). nArgBP2 mRNA is strongly detected in the habenula (F), and some expression is 
detected the hypothalamus (G). In midline coronal sections, nArgBP2 mRNA is 
expressed in the lateral septal nucleus (H) and the piriform cortex (I). 
Figure 4 – Generation and characterization of an anti-nArgBP2 antibody. A, ArgBP2 
and nArgBP2 isoforms express a sorbin homology domain and three SH3 domains, 
additionally; nArgBP2 includes a large region with a zinc finger domain. The anti-
nArgBP2 antibody was designed for the brain specific region. B, Antibody immunoblot 
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against lysates from HEK cells transfect with a nArgBP2 expression plasmid or empty 
vector. C, Immunocytochemistry of hippocampal neurons in culture transfected with 
nArgBP2 expression plasmid and non-transfected neurons (asterisk). D, Anti-nArgBP2 
antibody detects a single band in brain lysate, synaptosomal plasma membrane (SPM) 
and twice Triton X-100-extracted postsynaptic density (PSD-2T) fraction purified from 
mouse brain.  
Figure 5 – Protein expression of nArgBP2 across development. A, At P0, nArgBP2 
protein is expressed in the hippocampus and in the striatum. B, At P7, nArgBP2 is 
strongly expressed in the striatum, hippocampus and olfactory bulb and with 
moderately expressed in the cortex. C-D, nArgBP2 expression at P14 (C) and P21 (D) 
is concentrated in the hippocampal formation, cortical layers I, II/III, IV and VI, the 
striatum and several thalamic nuclei.  
Figure 6 – Detailed characterization of nArgBP2 protein expression in the adult mouse 
brain. A-B, Fluorescent immunohistochemistry reveals that nArgBP2 is enriched in 
several nuclei in the central nervous system. These include the accessory olfactory 
bulb (AOB), ventral thalamic nuclei (A) and amygdala (B). C-K, nArgBP2 expression is 
present in the glomeruli in the olfactory bulb (C), and layer II/III, IV and VI in the cortex 
(D), the striatum (E), amygdala (F), habenula (G), superior paraolivary nuclei (H), low 
levels of expression in the thalamus (VTN)  (I) and hypothalamic nucleus, but high 
levels of expression in the arcuate nucleus (J). Very high levels of expression of 
nArgBP2 are seen in the outer molecular layer in the dentate gyrus (K). 
Figure 7 – nArgBP2 does not co-localize with gephyrin at inhibitory synapses. A-D, 
Triple staining for endogenous nArgBP2 (A), gephyrin (B) and synapsin (C) in low 
density hippocampal neuron cultures. A’-D’ High power magnification indicates that 
puncta from gephyrin and nArgBP2 do not co-localize at postsynaptic sites. Scale bar 
50µm. 
Figure 8 – nArgBP2 co-localizes with PSD-95 at excitatory synaptic sites. A-D, Triple 
staining for endogenous nArgBP2 (A), PSD-95 (B) and synapsin (C) in low density 
hippocampal neuron cultures. A’-D’ 4x magnification indicate that nArgBP2 and PSD-95 
strongly localize to synaptic sites. A’’-D’’ Higher power magnification reveals an 
apposition between synapsin and PSD-95 and a strong overlap between PSD-95 and 
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nArgBP2 at postsynaptic sites. E, Analysis of signal intensity across pixel distance 
indicates that the signal peak for synapsin and PSD-95 is segregated, PSD-95 and 
nArgBP2 strongly co-localize although nArgBP2 signal peak is more distanced from the 
synapsin peak. Scale bar 50µm. 
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Abstract 
Bipolar disorder (BPD) is a debilitating condition with strong genetic heritability. 
Both disruptions in circadian rhythms and in the glutamatergic system have been 
implicated in this disorder. However, the identification of candidate genes and the 
generation of animal models with face, predictive and construct validity are necessary 
for a deeper understanding of BPD. Here we characterize the in vivo consequences of 
disrupting the neuronal Arg/Abl-binding protein 2 (nArgBP2), a postsynaptic density 
protein which interacts with the SAPAP/Shank complex at glutamatergic synapses. We 
show that mice with a targeted deletion for nArgBP2 exhibit hyperactivity in novel 
environments and home cage, display increased stereotypies, reduced depressive-like 
behaviors and a pronounced disruption in circadian rhythms, all endophenotypes of 
manic-like behavior. Lithium, a drug commonly prescribed to BPD patients successfully 
ameliorates the circadian rhythm dysfunction and corrects the reduced depressive-like 
behaviors in nArgBP2 mutant mice. Furthermore, we found that mild chronic stress 
challenges the nArgBP2 mutants into a depressive-like phenotype. Finally, using 
electrophysiology and biochemistry we uncover an increase in glutamatergic signaling 
and in glutamate receptor subunits at the synapse. These findings demonstrate that 
nArgBP2 plays an important role at glutamatergic synapses and that nArgBP2 mutant 
animals may be a valuable model to probe BPD. 
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Introduction 
Bipolar disorder (BPD) is a debilitating condition characterized by cyclic 
alterations in mood, ranging from manic and hypomanic affect to depression (American 
Psychiatric Association, 2000). BPD is diagnosed in patients after at least one manic 
episode with or without concurrent episodes of depression.  Some individuals can also 
undergo “rapid cycling” during which manic and depressive states have been reported 
to alternate up to 20 times in one year (Dunner et al., 1977). Although the triggering 
pathological events remain unknown, human genetic studies have provided evidences 
for the strong heritability in BPD (Craddock and Jones, 1999; McGuffin et al., 2003). 
Notably, in the general population BPD is thought to afflict 0.5-1.0% of individuals 
(Kessler et al., 1994; Craddock and Jones, 1999). On the other hand, monozygotic 
twins of BPD probands have a lifetime risk of 40-70% to develop this disorder and first 
degree relative of probands share a risk of 5-10% (Kessler et al., 1994; Craddock and 
Jones, 1999). Nevertheless, the identification of causative genes for BPD has been 
complicated by the presence of susceptibility regions in virtually every human 
chromosome (Serretti and Mandelli, 2008). Therefore, the diagnostic for BPD remains 
solely based on behavioral manifestations. 
From associated co-morbid conditions, sleep disorders are among the most 
prevalent in BPD (Jones, 2001). A range of 69 to 99% of patients experiencing manic 
episodes report a reduction in time spent sleeping and hypersomnia during depressive 
states (Harvey, 2008). Moreover, sleep disturbances are strong prodromal symptom of 
relapse into manic episodes and in the prediction of first BPD onset (Jackson et al., 
2003; Duffy et al., 2007; Sierra et al., 2007).  Furthermore, the link between sleep, 
circadian rhythms and bipolar disorder has also been modeled in mice. The ClockΔ19 
mutant mice display a disruption in circadian activity and also manifest several 
phenotypes reminiscent of manic-like behavior (Vitaterna et al., 1994; Roybal et al., 
2007). Convergent evidences for the link between BPD and circadian disruption also 
emerge from the behavioral and molecular effects of lithium on circadian biology. 
Lithium salts are a common therapeutic prescribed to BPD patients, and lithium is one 
of the few known substances that influence circadian activity at the behavioral level, 
possibly through the action on the circadian nuclear receptor Rev-erbα or the signaling 
protein GSK3β (Abe et al., 2000; Lenox et al., 2002; Jope, 2003; Yin et al., 2006). 
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At the neuronal and circuit level, dysfunction in glutamatergic signaling has also 
garnered substantial interest as a potential underlying cause for affective mood 
disorders (Du et al., 2004; Alt et al., 2006; Wilson et al., 2006; Sanacora et al., 2008; 
Shaltiel et al., 2008). The postsynaptic density (PSD) is a critical structure in 
glutamatergic synapses (Kennedy, 2000; Sheng and Hoogenraad, 2007) and mutations 
in genes coding for PSD proteins are known to give rise to several forms of mental 
disorders. In particular, the synaptic macromolecular complex composed of 
Neurexin/Neuroligin/PSD-95/SAPAP/Shank has been linked to a large number of 
human neuropsychiatric disorders (Bayes et al., 2011), including autism (Durand et al., 
2007; Berkel et al., 2010; Pinto et al., 2010), schizophrenia (Sudhof, 2008), obsessive-
compulsive disorder (Welch et al., 2007; Zuchner et al., 2009; Boardman et al., 2010) 
and mental retardation (Tarpey et al., 2004; Berkel et al., 2010). Therefore, the 
hypothesis that interaction between molecular partners leads to the development of 
disorders with partially overlapping endophenotypes, suggests a landscape of 
interrelated disorders which may originate from overlapping molecular causation (Goh 
et al., 2007; Oti et al., 2008; Barabasi et al., 2011).  
nArgBP2, a neuronal specific isoform of the SORBS2 gene, was identified 
through its interaction with the SAPAP family of proteins (Kawabe et al., 1999). 
nArgBP2 is phosphorylated by Abl and Arg protein-tyrosine kinases (Wang et al., 1997) 
and is proposed to regulate mechanisms converging on the actin cytoskeleton. 
nArgBP2 is synaptically enriched and well positioned to bridge the interaction between 
the PSD and the actin cytoskeleton (Kawabe et al., 1999; Cestra et al., 2005). At the 
protein structure level, nArgBP2 is composed of a conserved Sorbin homology domain 
(Kimura et al., 2001), a zinc finger domain and three SH3 domains near the C-terminus 
(Kawabe et al., 1999). The association of nArgBP2 to a complex of PSD proteins 
involved in other neuropsychiatric disorders (SAPAP3 in OCD (Welch et al., 2007) and 
Shank3 in autism (Peca et al., 2011a) highlights a potential role for this gene in related 
neuropsychiatric disorders. Moreover, SORBS2 localizes to a region of 4q35 implicated 
in bipolar disorder (Adams et al., 1998; Blair et al., 2002). Nevertheless, the in vivo 
function of nArgBP2 and its potential role in pathological conditions remains unknown. 
Therefore, in an effort to characterize the consequences of disrupting nArgBP2, we 
generated targeted mutant mice by homologous recombination in ES cells. A 
comprehensive behavioral analysis revealed that the nArgBP2 knockout mice display 
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spontaneous increased activity, increased explorative behavior, reduced depressive-
like behaviors and a disruption in circadian period length. Pharmacological intervention 
with lithium was shown to ameliorate the behavioral phenotypes reminiscent of manic-
like behavior, while conversely, challenging these animals with a paradigm of chronic 
stress switched them to a depressive-like state. Finally, biochemical and 
electrophysiological analysis uncovered an increase in glutamatergic synaptic signaling 
as a potential underlying source for the abnormal behaviors. 
Materials and Methods 
ES cells and PCR 
nArgBP2 mutant mice were generated by homologous recombination in R1 
mouse embryonic stem cells (Nagy et al., 1993) using standard procedures (Feng et 
al., 1998). The targeting vector was designed to disrupt the brain specific exon in the 
SORB2 gene (exon number 27; NIA mouse gene index #U009304) with the insertion of 
a NEO cassette. Genotypes were determined by PCR of mouse tail DNA using the 
primers FrtR2 (GGTTCTTTCCGCCTCAGG) and SAF (CCTGCCATGCCGCTCTGG) 
for the mutant allele (400 base pairs), and SAF and DelR 
(GTCTGGGAAGCTGTCGCAG) for the wildtype allele (300 base pairs). 
Southern Blot 
Southern blot of ES cells was performed according to standard methods(Feng 
et al., 1998). Briefly, a 1499bp probe, external to the short arm, was amplified with the 
following primers PF1 (CATGACGGTTCACAGCCATCTG) and PR1 
(CAGGCTTGGTGGCGAGTGCC). The probe was then hybridized to XbaI-digested ES 
cell genomic DNA, yielding a 8kb band for the wildtype allele and a 5kb band for the 
mutant allele. A similar procedure was repeated for post hoc confirmation of targeting 
using tissue from heterozygous mutant mice. 
PSD preparation and Western blot 
Purification of brain lysate, synaptosomal membrane fractions and PSD 
fractions of mouse brain were prepared as previously described (Welch et al., 2007; 
Peca et al., 2011b). Briefly, 3 µg of protein sample were ran on SDS-PAGE and probed 
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with specific antibodies. The relative amounts of β-actin (Sigma, #A5441) or β-tubulin 
(Sigma, #T4026) were used as loading control. Antibodies used in these experiments 
include antibodies against nArgBP2 (rabbit anti-nArgBP2 generated in our lab(Feliciano 
et al., 2011)) PSD-93 (gift from Dr. David Bredt); PSD-95 (Abcam #ab18258); SAP102 
(Calbiochem, #573902); SAPAP3 (previously described(Welch et al., 2004)); Shank3 
(NeuroMab, #75-109); Homer (Chemicon, #AB5875); NR1 (BD Biosciences, #556308); 
NR2A (Upstate, #05-901); NR2B (Upstate, #05-920); GluR1 (Abcam, #ab31232); 
GluR2 (Abcam, #ab20673); mGluR1/5 (Thermo Scientific, #PA1-4663); AKT (Cell 
Signaling Technology, #4691); AKT-pSer473 (Cell Signaling Technology, #4058); AKT-
pThr308 (Cell Signaling Technology, #2965); GSK3β (BD Biosciences, #610202); 
GSK3β-pSer9 (Cell Signaling Technology, #9336); PAK1 (Cell Signaling Technology, 
#2602); PAK1-pThr423 (Cell Signaling Technology, #2601). The antibody for SAPAP3 
has been previously described (Welch et al., 2004).  
Behavioral Tests 
All experimental procedures were reviewed and approved by the Duke 
University Institutional Animal Care and Use Committee (IACUC). Animals were housed 
3-5 per cage by genotype, at a constant 23 °C in a 12 h light/dark cycle (lights off at 
19:00), with food and water available ad libitum. For behavioral experiments we used 
age-matched 3-4 months old mice. All experiments were performed by experimenters 
blinded to the genotype of the animals. 
Immunohistochemistry 
Adult mouse immunohistochemistry was performed according to standard 
methods (Welch et al., 2007). Briefly, 50µm thick sections were collected from PFA 
fixed mouse brain, incubated with the anti-nArgBP2 antibody and an Alexa Fluor 488 
goat anti-rabbit secondary antibody (Invitrogen, Carlsbad, CA, USA). Images were 
collected on a Zeiss Axioskop 2 Plus (Carl Zeiss, Thornwood, NY, USA) with a Zeiss 
Neofluar 4X objective using a Zeiss Axiocam digital camera (Carl Zeiss). Images were 
assembled and processed using Adobe Photoshop (Adobe Systems, San Jose, CA, 
USA). 
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Motor and explorative behavior 
Open field: spontaneous locomotor activity was evaluated over 60 min in an 
automated Omnitech Digiscan apparatus (AccuScan Instruments) as described (Peca 
et al., 2011b). Locomotor activity was assessed as total distance traveled (m). Anxiety-
like behavior was defined by number of rearings and the time spent in the center as 
compared to time spent in the perimeter (thigmotaxis) of the open field. An automated 
measure of stereotypies in the open field test was defined as multiple breaks in the 
same beam (or set of beams), repeatedly and separated by less than 1 seconds (e.g. 
grooming). 
Running wheels: 3-4 months old animals were individually housed in a home 
cage containing a running wheel (Coulbourn Instruments, PA, USA). Multiple sets of 
running wheel cages were enclosed in an environment isolation chamber, which 
allowed the attenuation of sound, smells and permitted the control of the light/dark cycle 
(custom built). Activity counts were recorded using the ClockLab software (Actimetrics, 
IL, USA) and processed using MATLAB (MathWorks, MA, USA). Measures for activity 
were determined across 15 days in a 12-hour light/ 12-hour dark cycle. Each complete 
wheel turn corresponded to one activity count. 
Circadian rhythm 
Circadian rhythms: Identical equipment to the one described above. After a 2-3 
week period in a light/dark cycle, the animals were released into constant darkness. 
Animals were checked for health, food and water availability every week; bedding was 
changed every 2 weeks. For animals undergoing lithium treatment, and their controls, 
monitoring was performed every 5 days and the cage bedding was replaced every 10 
days. The monitoring of the animals and husbandry procedures were performed with 
minimal perturbation to the animals and under low intensity red-light (<50 lux). 
Determination of circadian period length was performed using a continuous interval of 
at least 10 days and calculated using the Lomb-Scargle periodogram. 
Light pulses: Sensitivity to photonic cues and circadian resetting was performed 
with a simplified Aschoff method(Aschoff, 1965; Refinetti, 2006) with only two time 
points, CT14 (circadian time 14) and CT24. In nocturnal animals, CT12 is the subjective 
night, hence, the start of activity. Briefly, using ClockLab, calculation of the subjective 
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circadian time was determined for each individual mouse and a 300 lux light exposure 
of 15min was administered at CT14, CT24 and the phase shifts calculated in ClockLab. 
Chronic mild stress: We adapted our circadian apparatus to induce a form of 
chronic mild stress by maintaining constant illumination for a period of 8 weeks. The 
animals were monitored for health status, food and water availability every week. 
Drug treatment 
Lithium treatment for running wheels: Mice were introduced in the running wheel 
apparatus and maintained on a LD cycle. During the first week the animals were fed a 
chow contained a low dose of lithium carbonate (1.2 g/kg) to reduce lithium toxicity. 
During the second week of LD, the animals were switch to a chow containing lithium 
carbonate at 2.4 g/kg. This dose was previously calculated to yield serum drug levels at 
concentrations similar to the therapeutic window for BPD patients (0.6 -1.2 mEq/L) (Du 
et al., 2008). Treatment continued for an additional 8 weeks under DD conditions. 
Lithium-containing chow and control chow were identical with the exception of the 
added drug (Bio-Serv, NJ, USA).  
Valproic acid treatment for running wheels: Chow containing sodium valproate 
was administered in a similar paradigm as described for lithium treatment; however, 
drug concentration in the chow was 10 g/kg for the low dose and 20 g/kg for the high 
dose (Bio-Serv, NJ, USA). Sodium valproate at 20 g/kg in the chow was previously 
determined to yield serum drug levels (bound + unbound) at concentrations similar to 
the therapeutic window for human patients (50 - 100 µg/mL) (Du et al., 2008). 
Lithium treatment for Forced Swim Test: Control and mutant mice were tested 
under the Forced Swim test (described below). The same cohort of animals was then 
treated for 1 week with low dose lithium carbonate-containing chow (1.2 g/kg) followed 
by 3 weeks of chow with lithium carbonate at 2.4 g/kg. 
Serum blood levels of lithium and valproic acid: Animals were deeply 
anesthetized, decapitated and trunk blood was collected for analysis of drug levels. 
Determination of drug serum levels was performed by Medtox (St. Paul, MN, USA). 
Forced Swim (Porsolt) Test 
The test animals were acclimatized to the testing room for 60 min prior to the 
trial and assigned a code to maintain blinded genotyping information. Mice were then 
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placed in a glass beaker (18 cm in diameter) containing water at 23-24 °C and their 
behavior videotaped for 10 min. Next, the mice were removed and placed in an empty 
cage to dry before being transferred to their home cage. The water was changed and 
the beaker cleaned between each subject. From the 10 min recorded for each animal, 
only the last 6 min of the test were scored for total time spent in immobility. The 
experimenter scoring the behavior was blinded to the animal genotype. Immobility was 
defined as the absence of volitional body or limb movement. 
Brain Slice preparation for extracellular field recording 
Acute brain slices were prepared from 3-4 month old mice. Slices were 
prepared from one WT and one nArgBP2 KO pair each day and the experimenter was 
blind to the genotypes.  The mice were deeply anesthetized by intra-peritoneal injection 
of Avertin and then transcardially perfused with 25 mL of carbogenated ice-cold 
protective cutting artificial cerebrospinal fluid (aCSF) with the composition (in mM): 185 
sucrose, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 25 glucose, 5 L-ascorbic acid, 3 Na-
pyruvate, 0.5 CaCl2.4H2O, 4 MgSO4.7H2O. Mice were then decapitated and the brains 
were removed into ice-cold cutting solution for an additional 1-minute.  The brains were 
then rapidly blocked and embedded in low gel point agarose (Sigma type I-B) for 
horizontal sectioning at 300 µM thickness on a VF200 model Compresstome 
(Precisionary Instruments) using either a sapphire or zirconium ceramic injector style 
blade.  Slices containing the middle 1/3 of the hippocampus (8 hemi-slices per brain) 
were immediately transferred to a holding chamber containing carbogenated aCSF (23-
25°C) of the composition (in mM): 119 NaCl, 2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 
12.5 glucose, 2 CaCl2.4H2O, 1 MgSO4.7H2O.  The holding aCSF was supplemented 
with (in mM): 5 L-ascorbic acid, 3 Na-pyruvate to improve slice health and longevity, 
and slices were recovered for a minimum of 1.5 hours and stored for a maximum of 6 
hours prior to transfer to the recording chamber for use.  The recording aCSF did not 
contain L-ascorbic acid or Na-pyruvate.  The osmolarity of all solutions was measured 
at 300-310 mOsm and the pH was maintained at ~7.3 after equilibration under constant 
carbogenation. 
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Extracellular field recording 
A pencil-tipped platinum iridium concentric bipolar stimulating electrode 
(CBAPC75, 25uM inner pole diameter; FHC) was placed on the outer 1/3 of the 
molecular layer of the suprapyramidal blade of the dentate gyrus. This electrode 
position was chosen to predominantly activate the lateral perforant pathway axons that 
originate from the entorhinal cortex and terminate onto the distal dendrites of 
hippocampal dentate granule cells.  A borosilicate glass recording electrode filled with 
2M NaCl was also placed within the outer 1/3 of the molecular layer at a separation of 
250-275 µm from the stimulating electrode tip.  The recording electrode was lowered 
into the slice to the depth that produced that maximal response size. The outer, middle, 
and inner portions of the molecular layer are easily distinguished under low power 
magnification (4X) using differential interference contrast (DIC) optics.  Electrode 
placement was further validated under high power magnification (40X) with the aid of 
900 nm infra-red DIC optics as needed.  Lateral perforant pathway to dentate gyrus 
extracellular field excitatory postsynaptic potentials (LPP-DG fEPSPs) were evoked 
with 0.15 ms step depolarizations at 30 µA test intensity at a baseline frequency of 
0.050 Hz.  Paired pulses were evoked with a 100 ms inter-stimulus interval.  LPP-DG 
fEPSPs exhibited PPF under these conditions, whereas medial perforant pathway 
responses (MPP-DG fEPSPs) exhibit PPD, as reported previously.  In preliminary 
recording we also verified the specificity of the electrode configuration for LPP-DG 
fEPSPs versus MPP-DG fEPSPs by examining the sensitivity to mGluR agonists.  LPP-
DG fEPSPs were reduced by the group III mGluR-selective agonist L-AP4 whereas 
MPP-DG fEPSPs were not affected. Conversely, MPP-DG fEPSPs were reduced by 
the group II mGluR-selective agonist DCGIV whereas LPP-DG fEPSPs were not 
affected. Thus, collectively we used morphological (visualization by DIC optics), 
electrophysiological (PPF vs. PPD), and pharmacological (sensitivity to mGluR 
agonists) criteria to confirm that the measured synaptic responses originated from 
selective stimulation of the lateral perforant pathway.  
After establishing a suitable recording configuration, evoked responses were 
monitored for a baseline period of 5 minutes to ensure stable LPP-DG fEPSP 
amplitude.  Care was taken to ensure that no population spike contamination occurred 
at the baseline intensity.  Input-output functions were then determined for the 
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presynaptic fiber volley (negative peak 1, NP1) and fEPSP amplitude by conducting 
three consecutive rounds of stimulation over a complete dynamic range from 0-80 µA in 
10 µA increments.  All recordings were performed at 30-32°C.   
Data acquisition and analysis 
Signals were acquired with custom protocols designed using pClamp 10 
software to control a Multiclamp 700B amplifier and Digidata 1440A (Axon 
Instruments/Molecular Devices). Data analysis was performed blind of the genotype of 
the experimental animals using Clamp Fit software (Axon Instruments/Molecular 
Devices). Response size for fEPSPs was measured as the absolute peak amplitude.  
Paired pulse ratio was calculated as the ratio of the 2nd population spike amplitude to 
the 1st population spike amplitude for responses to paired pulse stimulation at 30 µA 
fixed intensity with a 100 msec interstimulus interval for the pair.  Values are expressed 
as means ± s.e.m. and data were tested for significance using either an unpaired t-test 
or two-way repeated measures ANOVA using Prism software (Graph Pad). 
Morris water maze 
Morris water maze testing was performed as described with minor alterations 
(Peca et al., 2011b). Briefly, 3-4 months old mice were tested in a 120 cm diameter 
pool and the hidden platform was 8 cm in diameter. Pool water was maintained at 23 ± 
0.5 °C and made opaque by mixing-in white non-toxic tempera paint. During training 
and reversal training, 90 s duration trials were used. The probe trial was 30s in 
duration. The experimenter followed the animals’ progress using tracking software while 
situated outside of the testing room. Tracking and analysis were performed using the 
Noldus Ethovision software.  
Golgi staining and Sholl analysis.  
Golgi staining and Sholl analysis were performed as described(Peca et al., 
2011b). All brains and collected sections were coded in order to blind the experimenter 
of the genotype until after all data was collected and analyzed. Brains from 3-4 months 
old mice were prepared with standard Golgi–Cox impregnation techniques using the FD 
Rapid GolgiStain Kit (NeuroTechnologies). Granule cells in in the upper blade of the 
dentate were traced using a motorized microscope with a digital CCD camera 
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connected to a computer running Neurolucida Software (MBF Bioscience). The three-
dimensional analysis of the reconstructed neurons was performed using NeuroExplorer 
software (MBF Bioscience) and data from total dendritic length and neuronal complexity 
was analyzed in Prism (GraphPad). 
Hematoxylin & Eosin; Thionin and Timm Staining 
Hematoxylin & Eosin staining and thionin staining were performed according to 
standard methods(Welch et al., 2007). Timm staining was performed in 25 µm thick 
section using the FD Rapid TimmStain Kit according to manufacturers’ instructions 
(NeuroTechnologies).  
Results 
nArgBP2-/- mice display increased levels of spontaneous activity and explorative 
behavior 
In neurons, nArgBP2 is coded by the inclusion of a highly conserved exon 
normally not expressed outside of the brain (Cestra et al., 2005; Feliciano et al., 2011) 
(Fig. 1a). We targeted this brain specific exon in mouse ES cells to generate a 
perturbation in nArgBP2 (Fig. 1a) and confirmed our genetic manipulation through 
southern blotting of targeted ES cells (Fig. 1b), by PCR (Fig. 1c) and through western 
blotting in WT and nArgBP2-/- brain samples (Fig. 1d). Mice homozygous for the 
targeted deletion were born at the expected Mendelian ratio, were fertile and did not 
display any gross anatomical brain abnormalities; however, slightly enlarged ventricles 
were often present in nArgBP2 homozygous mutant mice (Supplementary Fig. 1). An 
initial behavioral screen designed to test exploration in a novel environment revealed 
that nArgBP2 mutant mice displayed an increase in spontaneous locomotor activity 
(Fig. 1e-f). Distance traveled in the open field test was significantly greater when 
compared to WT controls (Fig. 1e: 60min, WT 33.35 ± 3.160m, n=18; KO = 51.67 ± 
4.908m, n=18; p<0.001, mean ± s.e.m.). nArgBP2 mutant mice also displayed an 
increase in rearing, which is a form of vertical exploration anxiogenic to mice (Fig. 1f: 
60min, WT 124.94 ± 42.855; KO 288.22 ± 47.977, n=18; p<0.01, mean ± s.e.m.). 
However, distance traveled in the center of the open field was similar across genotypes 
(Fig. 1g: 60min, WT 11.06 ± 1.865m, n=18; KO 12.09 ± 2.016m; n=18, p>0.05, mean ± 
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s.e.m.). Additionally, time spent in stereotypical behaviors was increased in nArgBP2-/- 
mice (Fig. 1h: 60min, WT 911.69 ± 84.552s, n=18; KO 1118.63 ± 79.600s, n=18; 
p<0.05, mean ± s.e.m.). These results suggest that nArgBP2-/- mice display an increase 
in spontaneous activity and exploratory behavior in a novel environment.!
Disrupted circadian rhythms in nArgBP2-/- mice 
Our results suggesting a spontaneous hyperactivity in the open field prompted 
us to investigate if nArgBP2-/- mice also displayed increased levels of activity over 
longer periods of time. To this purpose, we tested singly housed, nArgBP2-/- and 
nArgBP2+/+ mice in a home cage setting each containing a running wheel. We found 
that across a 15 day period, nArgBP2 mutants displayed higher levels of activity in the 
running wheels, as measured by total number of wheel turns per 24h period (Fig. 2a). 
In the span of this analysis, we also interrogated the circadian function in nArgBP2-/- 
mice and uncovered a reduction in circadian period length during “free-running” trials. 
Mammals entrain biological functions such as sleep, activity and body temperature to 
external environmental cues. Among the most powerful influencing factors for the 
oscillation in circadian activity (i.e. a zeitgeber) is the day-night cycle. However, in the 
absence of zeitgebers (total darkness and absence of any rhythmic perturbation), sleep 
and activity patterns reveal the periodicity of the internal circadian clock (Lowrey and 
Takahashi, 2000). Using an apparatus isolated from external cues we found that both 
genotypes normally entrained to a 12h light-dark cycle (Fig. 2b-d). However, in dark-
dark conditions nArgBP2-/- mice displayed a significant reduction in period length (Fig. 
2e: WT: 24.18 ± 0.07157 h, n=10; KO: 23.37 ± 0.1049, n=10; p<0.001, mean ± s.e.m.). 
Occasionally, nArgBP2-/- mice exposed to long periods of dark-dark condition also lost 
rhythm periodicity (Fig. 2d). During dark-dark periods both genotypes remained 
respondent to phase shifts induced by photonic stimuli (Fig. 2e; Circadian Time 14h, 
WT: -2.164 ± 0.2h, n=10; KO: -1.941 ± 0.1699 h, n=10; p>0.05, mean ± s.e.m.). Our 
data suggests that nArgBP2-/- may display manic-like behaviors as measured by 
hyperactivity, increased explorative behavior and a dysfunction in internal circadian 
clock.  
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Lithium rescues the circadian period reduction in nArgBP2-/- mice and reverts the 
resistance to depressive-like behavior 
To attempt a pharmacological rescue of the manic-like behaviors and circadian 
abnormalities in the nArgBP2-/- mice, we treated mutants and controls with two drugs 
commonly prescribed to BPD patients: lithium, a mood stabilizer and valproic acid, an 
anticonvulsant. We chronically treated cohorts of animals during the light-dark 
entrainment period for 4 weeks before switching to a dark-dark environment and 
assessing internal clock function. Drugs were administered in the chow at 
concentrations that yield stable blood-level concentrations within therapeutic ranges 
((Du et al., 2008) and Supplementary Table 1). The six groups of animals consisted of 
naïve, lithium- or valproic acid-treated nArgBP2+/+ and nArgBP2-/- mice (Fig. 3a-f). 
Lithium treatment, but not valproic acid, significantly ameliorated the circadian period 
length dysfunction in the nArgBP2-/- mice (Fig. 3d-f). In these mice, lithium treatment 
produced an increase in period length by approximately 0.7h, while in control mice 
lithium produced an increase of only 0.16h. In both genotypes, valproic acid treatment 
led to a small, but not statistically significant reduction in period length (ANOVA, naïve 
vs treated, p>0.05). 
To determine if the manic-like behavior of nArgBP2-/- mice was accompanied by 
an inverse relationship in measures of rodent depressive-like behaviors we performed a 
Porsolt forced swim test. In this paradigm, nArgBP2-/- mice spent less time in immobility 
when compared to controls (Fig. 4a –left-). We again performed a pharmacological 
intervention and observed that chronic lithium treatment successfully rescued this 
phenotype (Fig. 4a – right-). Additionally, when analyzing animals that were tested 
before and after lithium treatment, we observed an inverse trend between genotypes, 
suggesting an anti-depressive effect of lithium in wildtype mice but an anti-manic effect 
on the mutant nArgBP2 mice (Fig. 4b). 
After testing, animals were sacrificed and the blood concentration of both drugs 
was found to be similar across genotypes and within proposed therapeutic levels 
(Supplementary Table 1). Together, our data of increased spontaneous activity, 
dysfunction in circadian rhythms, reduced depressive-like behavior and 
pharmacological rescue after lithium treatment, suggests that the nArgBP2 knockout 
mice display manic-like behaviors.!
!
119!
nArgBP2-/- mice display enhanced depressive-like behaviors after chronic mild 
stress!
Finally, we also explored the possibility that chronic mild stress would 
differentially affect nArgBP2-/- and control mice. To test this, we maintained a cohort of 
nArgBP2+/+ and nArgBP2-/- mice in the running wheel apparatus under constant 
illumination for 8 weeks (Fig. 4c). During the period of light/light, both genotypes lost 
circadian rhythmicity. After this period of extended stress, we removed the animals from 
the apparatus and performed the forced swim test. Under these conditions we observed 
that nArgBP2 mutant mice displayed an increase in time spent in immobility when 
compared to controls (Fig. 4d; WT: 148.0 ± 11.88s, n=9; KO: 216.4 ± 20.77s, n=9; 
p<0.05, mean ± s.e.m.). This data indicate that nArgBP2 mutant mice are prone to 
display depressive-like phenotypes after chronic, stress-induced challenges. 
Behavior inflexibility in nArgBP2-/- mice 
Behavioral inflexibility is a common clinical manifestation in humans undergoing 
manic episodes. To test if naïve nArgBP2 mutant mice also display behavioral rigidity or 
deficits in behavioral plasticity, we performed a Morris water maze paradigm with 
reversal training in 3-4 months old animals (Fig. 5). We observed that during the initial 
training (Day 1), nArgBP2-/- mice displayed a shorter latency to find the platform (Fig. 
5a). This was most likely due to a higher average swim velocity in the mutants during 
the first training day and not due to enhanced learning, since during the first trials the 
animals are unaware of the presence of the hidden platform (Trial 1-2 Day 1; WT: 16.20 
± 1.241 cm/s, n=9; KO: 19.62 ± 0.6035 cm/s, n=10). However, this difference was 
eliminated with repeated exposure to the water maze and the development of search 
patterns by both genotypes, suggesting that there is no enhancement/deficiency in 
spatial memory learning in the mutant animals (Fig. 5a). At day six we tested the 
animals in a probe trial (hidden platform removed) and determined that both genotypes 
spent a similar percent of time in the quadrant that previously contained the hidden 
platform, suggesting no overt perturbation in spatial memory formation (Fig. 5b-c). 
During reversal training, the platform was reintroduced, its location switched and the 
animals re-trained (Fig. 5d). In the reversal probe trial both genotypes again displayed 
an increase in time spent in the new target quadrant (Fig. 5e-f); however, nArgBP2-/- 
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mice displayed a small but significant larger percent of time spent in the previously 
correct quadrant (Fig. 5e SW; WT: 16.78 ± 2.678s, n=9; KO: 27.89 ± 3.716 s, n=10; 
p<0.05, mean ± s.e.m.). These data suggest that nArgBP2-/- mice display normal spatial 
learning and spatial memory formation but a deficiency in behavioral plasticity during 
the reversal process of memory extinction. 
Evidence for enhanced excitatory synaptic function at lateral perforant pathway 
to granule cell synapses in acute hippocampal brain slices from nArgBP2-/- mice 
Initial immunostaining experiments with our newly developed anti-nArgBP2 
antibody revealed that the nArgBP2 protein is highly enriched in the outer 1/3 of the 
dentate gyrus molecular layer corresponding to the lateral perforant pathway (LPP) 
inputs to dentate granule cells of the hippocampus (Fig. 6a). In light of this striking 
localization pattern, we analyzed dentate granule cell morphology by Golgi staining and 
the patterning of the dentate gyrus by Timm staining but did not uncover any overt 
morphological abnormalities (Supplementary Fig. 2).  
To probe the functional consequences of nArgBP2 deletion, we next performed 
extracellular field recordings from the outer 1/3 of the dentate gyrus molecular layer 
while stimulating LPP axons using the acute hippocampal brain slice preparation (Fig. 
6b). This configuration allowed us to assess the functional status of excitatory synapses 
formed by LPP axons onto the distal dendrites of dentate gyrus granule cells (denoted 
as LPP-DG). We recorded LPP-DG fEPSPs over a full dynamic range of stimulation 
intensities (0-60 µA) from 3-4 month old adult mice in standard aCSF at 29-32⁰C. 
Importantly, acute brain slices were prepared from one nArgBP2-/- mouse and one age-
matched wild-type control mouse each day, and the experimenter was blinded to the 
genotypes of the animals. We found that LPP-DG fEPSPs were significantly increased 
in brain slices from nArgBP2-/- mice when compared to controls (at maximal 60 µA 
stimulation intensity: nArgBP2 -/- = 1.68 ± 0.06 mV, wild-type = 1.43 ± 0.04 mV, 
p<0.001; Fig. 6c). In contrast, there was no significant difference in the fiber volley 
amplitude (negative peak 1 or NP1), a measure of axonal excitability, or paired-pulse 
ratio (PPR), a measure that is inversely proportional to presynaptic release probability 
(Fig. 6d,e). These findings are consistent with a postsynaptic origin of the increased 
synaptic responses. Together, these data suggest that nArgBP2 may play a role in the 
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regulation of glutamatergic synapses and that deletion of nArgBP2 in mice leads to 
enhanced postsynaptic glutamatergic responsiveness at LPP-DG synapses.  
Increased levels of glutamate receptor subunits in the PSD of nArgBP2-/- mice 
Next we assessed if the observed enhancement of glutamatergic signaling was 
accompanied by biochemical alterations in the composition of the PSD. Because PSD 
isolation from the outer molecular layer in dentate gyrus is impractical, we focused on 
the striatum since nArgBP2 is expressed both homogenously and at high levels in this 
region (Fig. 6a). We biochemically isolated PSDs from the striatum of 3-4 months old 
control and nArgBP2 mutant mice and performed semi-quantitative western blotting for 
PSD scaffolding proteins (Fig. 7a-b), glutamatergic receptor subunits (Fig. 7c-d) and 
signaling molecules (Fig. 7e-f). We found that several ionotropic glutamate receptor 
subunits displayed increased levels in the mutant mice when compared to controls (Fig. 
7b). These included NR1 and NR2B subunits of NMDA receptors and the GluR1 and 
GluR2 subunits of AMPA receptors. These results converge with the findings from 
dentate electrophysiology in suggesting an up-regulation in glutamatergic signaling as a 
consequence of the disruption in nArgBP2. 
Discussion 
The synaptic macromolecular complex composed of PSD-95/SAPAP/Shank and 
interaction partners has been shown to be important for the normal functioning of the 
mammalian brain. Mutations in the genes coding for these proteins and their molecular 
partners have been linked to a large variety of human psychiatric and developmental 
disorders (Tarpey et al., 2004; Durand et al., 2007; Welch et al., 2007; Sudhof, 2008; 
Zuchner et al., 2009; Berkel et al., 2010; Boardman et al., 2010; Pinto et al., 2010). We 
recently characterized the consequences of disrupting SAPAP3 and Shank3 in mice 
(Welch et al., 2007; Peca et al., 2011b) and we hypothesized that other binding 
partners to SAPAP3 at the postsynaptic site could also reveal important roles. Here, we 
focused on elucidating the in vivo function of nArgBP2, a protein known to interact with 
the SAPAP proteins at the PSD (Kawabe et al., 1999). After generating a mutation in 
the mouse genome to disrupt the production of nArgBP2 we performed a behavioral 
characterization in homozygous mutant mice. We observed that mutant nArgBP2 mice 
display several phenotypes reminiscent of manic behavior, including: increased 
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explorative behavior in a novel environment, increased stereotypies; hyperactivity in the 
home cage, reduction in circadian rhythm length, behavioral inflexibility and reduced 
depressive-like behavior. This led us to conclude that nArgBP2-/- mice display strong 
face validity towards manic-like behaviors. Interestingly, challenging these animals with 
a form of chronic mild stress led the nArgBP2-/- mice to display an increase in measures 
of depression when compared to controls, suggesting that these animals can alternate 
to a depressive state. Finally, to test predictive validity in modeling manic-like 
behaviors, we administered two drugs commonly prescribed to BPD and we found that 
lithium treatment successfully ameliorated several of the manic-like behavioral 
manifestations in nArgBP2-/- mice. Interestingly, nArgBP2 also displays construct 
validity to manic-depressive behavior since the region containing the nArgBP2 gene in 
humans -4q35- has been linked to susceptibility to BPD (Adams et al., 1998; Blair et al., 
2002). Finally, at the synaptic level we found converging evidences from 
electrophysiological recordings and biochemical data pointing to an increase in 
glutamatergic signaling in nArgBP2 knockout mice.  
Despite recent progress, the neurobiological substrates underlying BPD are still 
poorly understood. The identification of susceptibility genes and the generation of 
animal models are crucial to provide a better understanding on the molecular and 
synaptic pathways involved in pathological states. The animals we describe here 
provide a good starting point to dissect the mechanisms involved in BPD. Additionally, 
our results combined with previous evidences from human genetic linkage data call for 
a deep sequencing of the SORB2/nArgBP2 gene in BPD patients. 
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Figure legends 
Figure 1 – Increased levels of spontaneous activity in nArgBP2-/- mice during 
exploration of a novel environment. a, Gene structure and functional domains in the 
SORBS2 gene (top); targeted locus and position of Southern blot probe (middle); and 
targeting vector (bottom). b, Southern blot of wildtype (WT) and targeted ES cells (ES+) 
after digestion with XbaI; 5kb band is present in targeted ES clones. c, PCR with DNA 
from tail sample of wildtype (+/+), heterozygous mutant (+/-) and homozygous nArgBP2 
mutant mice (-/-). d, Western blot from forebrain brain lysate, synaptosomal plasma 
membrane fraction (SPM) and PSD 2xTriton washed (2T) fractions in wildtype (+/+) and 
knockout mice (-/-) probed with anti-nArgBP2 (top) and β-tubulin antibodies (bottom).   
e-g, In an open field test for exploratory behavior in a novel environment, nArgBP2-/- 
mice, when compared to controls, displayed hyperactivity as measured by total 
distanced traveled (e), increased vertical exploratory behaviors (f), but similar distance 
traveled in the center of the open field (g). h, When analyzing stereotypies in the open 
field, nArgBP2-/- mice, when compared to controls, spent a larger amount of time 
performing repetitive movements. g-h;* p<0.05, **p<0.01, p<0.001, Two-way repeated 
measures ANOVA, data presented as means ± s.e.m. from n=18; 3-4 month old 
animals per group. 
Figure 2 – Increased levels of activity in the home cage and disrupted circadian 
rhythms in nArgBP2-/- mice. a, When compared to controls, nArgBP2-/- mice displayed 
increased levels of activity in the running wheels during a 15 day period (light-dark).    
b-e, In the same running-wheel setup, both nArgBP2-/- and wildtype mice display 
normal entrainment to 12h light-12h dark cycles (Light-Dark Entrainment); after 
switching the animals to total darkness (“Free-Running” Circadian), nArgBP2-/- mice 
display a sharp reduction in internal circadian periodicity (e), and will occasionally lose 
all rhythmicity (d - bottom). f-g, Sensitivity to photonic cues is not lost during “dark-dark” 
and both nArgBP2-/- and wildtype mice display similar phase shifts after a 15min 300 lux 
pulse at both Circadian Time –CT- 14 (f) or CT 22 (g). * p<0.05, p<0.001, Two-way 
repeated measures ANOVA for a, Student’s t-test for e-g, data presented as means ± 
s.e.m. from n=10; 3-4 month old animals per group.  
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Figure 3 – Lithium treatment rescues circadian abnormalities in nArgBP2-/- mice.         
a-f, Cohorts of naïve wildtype (a) and nArgBP2-/- mice (b), lithium treated (b and e) or 
valproic acid treated (c and d) were tested for circadian rhythm in light-dark and dark-
dark cycles. g, Lithium, but not valproic acid treatment, significantly rescue the circadian 
deficit in nArgBP2-/- mice.  * p<0.05, Student’s t-test, data presented as means ± s.e.m. 
from n=5-11 mice per group. 
Figure 4 – nArgBP2-/- mice display lower levels of depressive-like behavior under basal 
conditions, but enhanced depressive-like behaviors after chronic mild stress. a, Naïve 
nArgBP2-/- mice, when compared to controls, display less time spent in immobility in the 
forced swim test. However, lithium treatment normalizes their response. b, Analyzing 
the same animals tested before lithium treatment and 4 weeks after treatment reveals 
an inverse trend between genotypes in the forced swim test, producing an anti-manic 
effect in nArgBP2-/- mice and a mild anti-depressive effect in wildtype controls. c-d, After 
subjecting nArgBP2-/- and wildtype mice to prolonged 24h light, both genotypes lose 
circadian rhythmicity (c). Additionally, testing the same animals after the stress 
paradigm in the forced swim test, revealed that the nArgBP2-/- mice spend more time in 
immobility when compared to controls (d). * p<0.05, Student’s t-test, data presented as 
means ± s.e.m. from n=8-10 mice per group. 
Figure 5 – Behavioral inflexibility in nArgBP2-/- mice. a-b, Latency to find the hidden 
platform (SW) decreases significantly across 5 days of training for both wildtype and 
nArgBP2-/- mice (a). In the probe trial, when compared to controls, nArgBP2-/- mice 
spent a similar amount of time in target quadrant (SW) (b). c, Representative heat maps 
examples from control (WT) and nArgBP2-/- (KO) during the probe trial. d-e, Latency to 
find the platform decreases significantly across subsequent 5 days of reversal training 
(platform switched to NE) for both wildtype and nArgBP2-/- mice (d). In the reversal 
probe trial, when compared to controls, nArgBP2-/- mice spent a larger percent of time 
in the previously correct quadrant (SW), but still display preference for the new target 
quadrant (NE). f, Representative example heat maps from control (WT) and nArgBP2-/- 
mice (KO) during the reversal probe trial. *p<0.05, Student’s t-test, all data are 
presented as means ± s.e.m; n=9 for wildtype, n=10 for nArgBP2-/- mice. 
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Figure 6 – Increased field excitatory postsynaptic currents in nArgBP2-/- dentate gyrus. 
a-b, Immunohistochemistry in a wildtype mouse brain section stained with anti-nArgBP2 
antibody .a-b, nArgBP2 is highly enriched in the cortex, striatum and dentate gyrus (a). 
Dentate gyrus 2x magnification displaying an enrichment of nArgBP2 in the outer 
molecular layer and illustrative representation of recording and stimulation electrode 
positioning. c-e, Outer molecular layer fEPSP amplitude is increased in nArgBP2-/- mice 
(red) when compared to controls (black) (c); NP1 amplitude (d) and PPR (e) are not 
significantly different between nArgBP2-/- and control mice in field recordings. ** p<0.01, 
*** p<0.001; Two-Way repeated measures ANOVA, with Bonferroni post hoc test for c 
and d, Student’s t-test for e; all data presented as means ± s.e.m. from n= 34 slices/8 
mice (WT) and n= 29 slices/8 mice (KO). 
Figure 7 – Increased glutamatergic subunits in nArgBP2-/- striatal PSDs. a-f, PSD 
samples from nArgBP2-/- and controls were probed for PSD scaffolding proteins (a,b), 
glutamate receptor channel subunits (b-c) and signaling proteins (e-f). Significant 
changes were observed for NMDA receptor subunits, NR1, NR2B and AMPA receptor 
subunits, GluR1 and GluR2. * p<0.05, ** p<0.01, *** p<0.001, Student’s t-test, data 
presented as means ± s.e.m. from n=3-9 samples per group. 
Supplementary Figure 1 – Normal brain anatomy but enlarged ventricles in nArgBP2-/- 
mice. a-b, Thionin (a) and Hematoxylin and eosin (b) stain in three wildtype and three 
nArgBP2-/-reveals no gross abnormal anatomical defects but slightly enlarged ventricles 
in nArgBP2 knockout mice. 
Supplementary Figure 2 – Normal dendritic morphology and patterning in nArgBP2-/- 
dentate gyrus. a-b, Sholl analysis of Golgi stained neurons reveals a similar dendritic 
complexity between nArgBP2-/- and wildtype dentate granule cells (a); total dendritic 
length is not significantly different between genotypes (b). c, Example sections of 
wildtype (WT) and  nArgBP2-/- (KO) dentate gyrus after Golgi staining. d, Timm staining 
reveals a normal layer patterning in dentate gyrus from nArgBP2-/- mice when 
compared to controls. Two-Way repeated measures ANOVA, with Bonferroni post hoc 
test for a, Student’s t-test for b; all data presented as means ± s.e.m. from n= 36 
slices/3 mice (WT) and n= 36 slices/3 mice (KO). 
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Supplementary Table 1 – Serum blood levels of lithium and valproic acid in nArgBP2-/- 
and wildtype mice. Sodium valproate at 20 g/kg in the chow yielded serum drug levels 
(bound + unbound) at concentrations similar to the therapeutic window for human 
patients (50 - 100 µg/mL). Lithium carbonate at 2.4 g/kg in the chow yielded serum drug 
levels at concentrations similar to the therapeutic window for BPD patients (0.6 -1.2 
mEq/L).  
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Final Discussion 
An emerging theory proposes that several neuropsychiatric and developmental 
brain disorders are indeed ‘synapsopathies’ — synaptic development disorders or 
dysfunctions in synaptic plasticity (Bear et al., 2008; Zoghbi, 2003). This has been 
further confirmed by the involvement of a very large number of genes that code for 
proteins of the PSD in as many as 133 neurological, psychiatric and genetic disorders 
that affect the nervous system (Bayes et al., 2011). The works presented here adds 
support to this hypothesis and explores the role of nArgBP2 and Shank3 in vivo and 
how mutations in these genes influence synaptic function and behavior.  
We observed that mutant nArgBP2 mice display several phenotypes 
reminiscent of manic behavior, while challenging these animals with a form of chronic 
mild stress led them to display an increase in measures of depressive-like behavior. 
Predictive validity was also tested by administering two drugs commonly prescribed to 
BPD patients – Valproic acid and Lithium. From these, lithium was found to ameliorate 
several of the manic-like behavioral manifestations in nArgBP2-/- mice. 
We also generated and characterized two mutant mouse lines for the Shank3 
gene. In this work we found that the cortico-striatal circuitry is dysfunctional following 
mutations in the Shank3 gene and that behaviorally the animals display increased 
grooming behaviors and deficits in social interaction. From the two Shank3 lines 
generated, a grade effect was correlated with the severity of the genetic lesion, with the 
more severe of the two causing significant synaptic dysfunction and overt abnormal 
behavioral phenotypes. 
Nevertheless, while we made contributions to further understand the role of 
these proteins, the consequences of their lesion at the genetic level and gained insights 
in the affected circuits, several more questions are waiting further investigation. 
Regarding nArgBP2, it will still be important to probe which cellular mechanism may be 
playing a role in the up-regulation in glutamate signaling. Also, could endogenous 
nArgBP2 function as a negative regulator for the synaptic expression and regulation of 
glutamate receptors? Why are the nArgBP2 mutant mice sensitive to lithium and not 
valproic acid? Could this be relevant for human treatments or drug specificity for a 
subtype of BPD? What is the exact role played by the nArgBP2 brain-specific exon, 
why is it preserved across evolution with extremely high degree of conservation and by 
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which mechanisms it is only expressed in the brain? Does nArgBP2 play a role in the 
molecular clock oscillations? 
Regarding Shank3, we and others have now shown that indeed a dysfunction in 
this gene causes autistic-like behaviors in mice. Evidences presented also point to a 
dysfunction in cortico-striatal circuits which may be the proximal cause for the 
excessive grooming behavior. Nevertheless, it is not well establish if this is the main 
source for the deficiencies seen in social interaction. Therefore, these animals may 
provide a powerful tool to dissect the brain circuitry involved in the regulation of social 
interactions. Other questions that are still unaddressed and remain relevant include 
knowing if a genetic postnatal rescue of Shank3 will rescue the synaptic and behavioral 
abnormalities. Considerable progress has been made in this area for other disorders, 
also of a genetic origin and also considered to be developmental in nature. For 
example, advances have been made in showing that a postnatal rescue of MECP2 
(Rett Syndrome) and FMRP (Fragile-X Syndrome) expression can ameliorate or delay 
several of the abnormalities seen in the mouse models for these disorders (Giacometti 
et al., 2007; Guo et al., 2011; Guy et al., 2007; Zeier et al., 2009). Therefore it would be 
interesting to understand if a similar phenomenon could occur for a Shank3 genetic 
rescue. If answered in the affirmative, this would further support the shift in paradigm 
now considering developmental disorder as potentially “reversible”.  
More broadly, one aspect still eluding precise understanding is the fact that the 
same gene or genes in the same family can trigger different disorders. For genetic 
products producing interrelated and interacting proteins, this may be explained by 
better comprehending their expression pattern in the mammalian brain, and potentially 
addressing which particular circuits are affected, and hence, which of these circuits 
contribute to discrete phenotypes. However, the origin of different disorders by 
mutations in the same gene still requires further investigation. This, for example, is the 
case for Shank3 which has been strongly linked to autism, but also schizophrenia. Here 
the solution may reside at understanding local differences between expression of 
isoforms, gradation of the deleterious mutations or the potential effect of environmental 
and/or other genetic factors. The generation of knock-in animals that replicate discrete 
human mutations may also produce novel insights into these questions. 
Our understanding of human disorders is increasing at a rapid pace. The 
synergy between findings stemming from better diagnostic protocols, human genetic 
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data and functional studies performed in animal models will continue to produce 
important insights into the fundamental basic neurobiological phenomena and hopefully 
also coalesce into advances for more effective therapies aimed at these disorders.!
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